# DuPont de Nemours, Inc.: Form 10-Q for the period ended Sep 30, 2018

- Company: [DuPont de Nemours, Inc.](/companies/dd.md) (CIK 1666700)
- Form: 10-Q
- Filed: 2018-11-02
- Accepted by EDGAR: Nov 2, 2018, 10:10 ET
- Period: 2018-09-30
- Accession: 0001666700-18-000060
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1666700/000166670018000060/dowdupont3q18093018.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1666700/000166670018000060/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $20.12bn | us-gaap:Revenues |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $65.88bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2018-07-01 to 2018-09-30 | $15.48bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2018-01-01 to 2018-09-30 | $49.77bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months, 2018-07-01 to 2018-09-30 | $740.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2018-01-01 to 2018-09-30 | $2.31bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2018-07-01 to 2018-09-30 | $1.50bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2018-01-01 to 2018-09-30 | $5.14bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Income tax | 3 months, 2018-07-01 to 2018-09-30 | $320.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2018-01-01 to 2018-09-30 | $1.27bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | $497.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | $3.37bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | $0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | $1.44 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-07-01 to 2018-09-30 | $0.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2018-01-01 to 2018-09-30 | $1.45 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-07-01 to 2018-09-30 | 2,311,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2018-01-01 to 2018-09-30 | 2,323,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | −$370.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2018-07-01 to 2018-09-30 | $972.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Capital expenditure | 9 months, 2018-01-01 to 2018-09-30 | $2.56bn | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months, 2018-01-01 to 2018-09-30 | $2.63bn | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2018-01-01 to 2018-09-30 | $3.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-09-30 | $6.94bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $45.41bn | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $184.45bn | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $27.68bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2018-09-30 | $30.41bn | us-gaap:LongTermDebt |
| Shareholders' equity | at 2018-09-30 | $98.09bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 127,813 characters.

On December 11, 2015, The Dow Chemical Company ("Dow") and E. I. du Pont de Nemours and Company ("DuPont") entered into an Agreement and Plan of Merger ("Merger Agreement"), as amended on March 31, 2017, to effect an all-stock merger of equals strategic combination resulting in a newly formed corporation named DowDuPont Inc. ("DowDuPont" or the "Company"). On August 31, 2017, pursuant to the Merger Agreement, Dow and DuPont each merged with wholly owned subsidiaries of DowDuPont ("Mergers") and, as a result of the Mergers, Dow and DuPont became subsidiaries of DowDuPont (collectively, the "Merger"). Prior to the Merger, DowDuPont did not conduct any business activities other than those required for its formation and matters contemplated by the Merger Agreement. Dow was determined to be the accounting acquirer in the Merger. As a result, the historical financial statements of Dow for the periods prior to the Merger are considered to be the historical financial statements of DowDuPont. The results of DuPont are included in DowDuPont's consolidated results from the Merger date forward.

DowDuPont intends to pursue, subject to the receipt of approval by the Board of Directors ("Board") of DowDuPont and customary closing conditions, the separation of the combined Company's agriculture, materials science and specialty products businesses through one or more tax-efficient transactions ("Intended Business Separations").

Except as otherwise indicated by the context, the term "Dow" includes Dow and its consolidated subsidiaries, "DuPont" includes DuPont and its consolidated subsidiaries, "Union Carbide" means Union Carbide Corporation, a wholly owned subsidiary of Dow, and "Dow Silicones" means Dow Silicones Corporation (formerly known as Dow Corning Corporation, which changed its name effective as of February 1, 2018), a wholly owned subsidiary of Dow.

### Items Affecting Comparability of Financial Results

Due to the size of each of Dow's and DuPont's businesses prior to the Merger, in this section certain supplemental unaudited pro forma financial information is provided that assumes the Merger had been consummated on January 1, 2016. Adjustments have been made in the unaudited pro forma financial information for (1) the preliminary purchase accounting impact, (2) accounting policy alignment, (3) the elimination of the effect of events that are directly attributable to the Merger Agreement (e.g., one-time transaction costs), (4) the elimination of the impact of transactions between Dow and DuPont, and (5) the elimination of the effect of consummated divestitures required as a condition of regulatory approval for the Merger. Events that are not expected to have a continuing impact on the combined results (e.g., inventory step-up costs) are excluded. These adjustments impacted the consolidated results as well as the reportable segments. For additional information, see the Supplemental Unaudited Pro Forma Combined Financial Information in this section.

### OVERVIEW

The following is a summary of the results from continuing operations for the three months ended September 30, 2018:

- The Company reported net sales in the third quarter of 2018 of $20.1 billion, up 31 percent from $15.4 billion in the third quarter of 2017, with broad-based sales growth across all segments and geographic regions. Portfolio & Other contributed 22 percent of the sales increase, primarily reflecting the Merger, which impacted all segments except Performance Materials & Coatings and Industrial Intermediates & Infrastructure.
- Local price was up 6 percent compared with the same period last year, primarily in response to higher feedstock and raw material costs. Local price increased in all operating segments, except Electronics & Imaging (down 1 percent), including a double-digit increase in Performance Materials & Coatings (up 13 percent). Local price increased in all geographic regions.
- Volume increased 4 percent compared with the third quarter of 2017, with increases in all operating segments, except Nutrition & Biosciences (down 4 percent) and Performance Materials & Coatings (down 1 percent), including a double-digit increase in Industrial Intermediates & Infrastructure (up 14 percent). Volume increased in all geographic regions, led by a double-digit increase in Asia Pacific (up 12 percent).
- Currency had an unfavorable impact of 1 percent on sales, driven primarily by Latin America.
- Research and development ("R&D") expenses totaled $740 million in the third quarter of 2018, up from $528 million in the third quarter of 2017. Selling, general and administrative ("SG&A") expenses were $1,496 million in the third quarter of 2018, up from $1,001 million in the third quarter of 2017. R&D and SG&A expenses increased primarily due to the Merger.
- Restructuring and asset related charges - net were $290 million in the third quarter of 2018, consisting of $67 million of severance and related benefit costs, $86 million of asset write-downs and write-offs and $9 million of costs associated with

exit and disposal activities related to the DowDuPont Cost Synergy Program (the “Synergy Program”); asset impairments of $126 million; and $2 million of other.

- Integration and separation costs were $666 million in the third quarter of 2018, up from $354 million in the third quarter of 2017, reflecting post-Merger integration and Intended Business Separation activities.
- Equity in earnings of nonconsolidated affiliates was $178 million in the third quarter of 2018, up from $152 million in the third quarter of 2017, as higher earnings from the Kuwait joint ventures were partially offset by lower equity earnings from the Thai joint ventures.
- Sundry income (expense) - net was income of $47 million in the third quarter of 2018, down from income of $394 million in the third quarter of 2017, reflecting an increase in foreign exchange losses which was partially offset by income related to non-operating pension and other postretirement benefit plans. The third quarter of 2017 also included a $227 million gain from Dow's divestiture of the global ethylene acrylic acid copolymers and ionomers business ("EAA Business").
- On June 25, 2018, the Company announced that its Board declared a dividend of $0.38 per share, paid on September 14, 2018, to shareholders of record on August 31, 2018.
- The Company spent $1 billion on repurchases of DowDuPont common stock in the third quarter of 2018, completing the share repurchase program announced on November 2, 2017.
- In the third quarter of 2018, Dow and DuPont each made discretionary contributions of $1,100 million to their respective principal U.S. pension plans.

In addition to the financial highlights above, the following events occurred during or subsequent to the third quarter of 2018:

- The Form 10 registration statement for the separation of DowDuPont's materials science business (filed as Dow Holdings Inc.) was filed with the U.S. Securities and Exchange Commission ("SEC") on September 7, 2018, as amended on October 19, 2018.
- On September 12, 2018, Dow announced new low capital intensity, high return investments in its upstream and downstream silicones franchise to accelerate innovation and support global customer demand in high growth markets. The investment plans include a series of incremental siloxane debottlenecking and efficiency improvement projects, a new hydroxyl functional siloxane polymer plant in Carrollton, Kentucky, and additional expansion projects to increase capacity in performance silicones products and intermediates, including a new specialty resin plant in Zhangjiagang, Jiangsu, China.
- On October 11, 2018, the Company announced that its Board declared a dividend of $0.38 per share, payable on December 14, 2018, to shareholders of record on November 30, 2018.
- The initial Form 10 registration statement for the separation of DowDuPont's agriculture business (filed as Corteva, Inc.) was filed with the SEC on October 18, 2018.
- On November 1, 2018, the Company announced a new $3 billion share buyback program, which expires on March 31, 2019 - commensurate with the expected timing of the materials science spin-off.
- On November 1, 2018, the Company announced the capital structure for each of the three intended companies, including targeted credit ratings, operating cash and adjusted debt levels.
- On November 1, 2018, the Company announced it is increasing its cost synergy commitment from $3.3 billion to $3.6 billion.

*In millions, except per share amounts*

| Selected Financial Data | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $20,123 | $15,354 | $65,878 | $42,418 |
| Cost of sales ("COS") | $15,477 | $12,186 | $49,766 | $33,141 |
| Percent of net sales | 76.9% | 79.4% | 75.5% | 78.1% |
| Research and development expenses | $740 | $528 | $2,311 | $1,355 |
| Percent of net sales | 3.7% | 3.4% | 3.5% | 3.2% |
| Selling, general and administrative expenses | $1,496 | $1,001 | $5,143 | $2,480 |
| Percent of net sales | 7.4% | 6.5% | 7.8% | 5.8% |
| Effective tax rate | 37.4% | 50.8% | 26.7% | 30.5% |
| Net income available for common stockholders | $497 | $514 | $3,369 | $2,723 |
| Earnings per common share – basic | $0.22 | $0.32 | $1.45 | $2.04 |
| Earnings per common share – diluted | $0.21 | $0.32 | $1.44 | $2.01 |

58

### RESULTS OF OPERATIONS

*In millions*

| Summary of Sales Results | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $20,123 | $15,354 | $65,878 | $42,418 |
| Pro forma net sales |  | $18,285 |  | $59,469 |

### As Reported Net Sales in the Current Period Compared with As Reported Net Sales in the Prior Period

*Sales Variances by Segment and Geographic Region - As Reported*

| Percentage change from prior year | Three Months Ended Sep 30, 2018 Local Price & Product Mix | Currency | Volume | Portfolio & Other 1 | Total | Nine Months Ended Sep 30, 2018 Local Price & Product Mix | Currency | Volume | Portfolio & Other 1 | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Agriculture | 3% | (5)% | 3% | 26% | 27% | 2% | —% | (2)% | 143% | 143% |
| Performance Materials & Coatings | 13 | (1) | (1) | — | 11 | 11 | 2 | (1) | — | 12 |
| Industrial Intermediates & Infrastructure | 5 | (1) | 14 | — | 18 | 8 | 2 | 16 | — | 26 |
| Packaging & Specialty Plastics | 7 | — | 5 | 4 | 16 | 4 | 2 | 7 | 6 | 19 |
| Electronics & Imaging | (1) | — | 3 | 42 | 44 | — | 1 | 2 | 61 | 64 |
| Nutrition & Biosciences | 2 | (2) | (4) | 150 | 146 | 3 | — | — | 327 | 330 |
| Transportation & Advanced Polymers | 4 | (1) | 1 | 117 | 121 | 3 | 2 | 1 | 245 | 251 |
| Safety & Construction | 2 | (1) | 5 | 71 | 77 | 2 | 1 | 2 | 135 | 140 |
| Total | 6% | (1)% | 4% | 22% | 31% | 5% | 2% | 5% | 43% | 55% |
| U.S. & Canada | 7% | —% | 1% | 19% | 27% | 5% | —% | 2% | 51% | 58% |
| EMEA 2 | 8 | (1) | 1 | 19 | 27 | 6 | 6 | 3 | 36 | 51 |
| Asia Pacific | 4 | (1) | 12 | 30 | 45 | 4 | 1 | 16 | 46 | 67 |
| Latin America | 4 | (4) | 6 | 20 | 26 | 6 | (2) | 3 | 27 | 34 |
| Total | 6% | (1)% | 4% | 22% | 31% | 5% | 2% | 5% | 43% | 55% |

1\. Portfolio & Other primarily reflects sales related to the Merger (impacts all segments, except Performance Materials & Coatings and Industrial Intermediates & Infrastructure). Portfolio & Other also includes sales for the acquisition of FMC Corporation's ("FMC") Health and Nutrition Business (the "H&N Business") acquired on November 1, 2017, impacting Nutrition & Biosciences. Portfolio & Other also reflects the following divestitures: a portion of Dow AgroSciences' Brazil corn seed business ("DAS Divested Ag Business"), divested on November 30, 2017 (impacting Agriculture), the EAA Business, divested on September 1, 2017 (impacting Packaging & Specialty Plastics) and SKC Haas Display Films group of companies, divested June 30, 2017 (impacting Electronics & Imaging).

2\. Europe, Middle East and Africa.

The Company reported net sales in the third quarter of 2018 of $20.1 billion, up 31 percent from $15.4 billion in the third quarter of 2017, primarily due to the Merger, increased selling prices and demand growth, reflecting additional capacity from U.S. Gulf Coast growth projects and increased supply from Sadara Chemical Company ("Sadara"). Sales growth was broad-based with increases in all segments and geographic regions. Portfolio & Other changes contributed 22 percent of the sales increase, primarily reflecting the Merger, and impacted all segments, except Performance Materials & Coatings and Industrial Intermediates & Infrastructure. Local price was up 6 percent compared with the same period last year, in response to higher feedstock and raw material costs. Local price increased in all geographic regions and most segments, with the most notable increases in Performance Materials & Coatings (up 13 percent), Packaging & Specialty Plastics (up 7 percent) and Industrial Intermediates & Infrastructure (up 5 percent), which were partially offset by a decrease in Electronics & Imaging (down 1 percent). Volume increased 4 percent with gains in most segments, except Nutrition & Biosciences (down 4 percent) and Performance Materials & Coatings (down 1 percent). The most notable volume increases were in Industrial Intermediates & Infrastructure (up 14 percent), Packaging & Specialty Plastics and Safety & Construction (both up 5 percent). Volume increased in all geographic regions, including a double-digit increase in Asia Pacific (up 12 percent). Currency was down 1 percent compared with the same period last year, driven primarily by Latin America currencies (down 4 percent).

Net sales for the first nine months of 2018 were $65.9 billion, up 55 percent from $42.4 billion in the same period last year, driven by the Merger, higher sales volume, reflecting additional capacity from U.S. Gulf Coast growth projects and increased supply from Sadara, increased selling prices and the favorable impact of currency. Sales growth was broad-based with increases in all segments and geographic regions. Portfolio & Other changes contributed 43 percent of the sales increase, primarily reflecting the Merger. Volume increased 5 percent compared with the same period last year, as increases in Industrial Intermediates & Infrastructure (up 16 percent), Packaging & Specialty Plastics (up 7 percent), Electronics & Imaging and Safety & Construction

(both up 2 percent) and Transportation & Advanced Polymers (up 1 percent) more than offset declines in Agriculture (down 2 percent) and Performance Materials & Coatings (down 1 percent). Nutrition & Biosciences volume was flat. Volume increased in all geographic regions, including a double-digit increase in Asia Pacific (up 16 percent). Local price was up 5 percent compared with the same period last year, with increases in all geographic regions, driven by pricing initiatives in response to higher feedstock and raw material costs. Local price increased in most segments, with the most notable increases in Performance Materials & Coatings (up 11 percent), Industrial Intermediates & Infrastructure (up 8 percent) and Packaging & Specialty Plastics (up 4 percent). Local price in Electronics & Imaging was flat. Currency was up 2 percent compared with the same period last year, driven primarily by EMEA (up 6 percent).

### As Reported Net Sales in the Current Period Compared with Pro Forma Net Sales in the Prior Period

*Sales Variances by Segment and Geographic Region - Net Sales in Current Period Compared with Pro Forma Net Sales in Prior Period*

| Percentage change from prior year | Three Months Ended Sep 30, 2018 Local Price & Product Mix | Currency | Volume | Portfolio & Other 1 | Total | Nine Months Ended Sep 30, 2018 Local Price & Product Mix | Currency | Volume | Portfolio & Other 1 | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Agriculture | 3% | (6)% | 8% | (3)% | 2% | 3% | 1% | (4)% | (1)% | (1)% |
| Performance Materials & Coatings | 13 | (1) | (1) | — | 11 | 11 | 2 | — | — | 13 |
| Industrial Intermediates & Infrastructure | 5 | (1) | 14 | — | 18 | 8 | 2 | 16 | — | 26 |
| Packaging & Specialty Plastics | 6 | — | 5 | — | 11 | 3 | 2 | 7 | — | 12 |
| Electronics & Imaging | (1) | — | 1 | — | — | — | 1 | 1 | (3) | (1) |
| Nutrition & Biosciences | 1 | (1) | 3 | 11 | 14 | — | 2 | 4 | 12 | 18 |
| Transportation & Advanced Polymers | 6 | (1) | 3 | — | 8 | 5 | 3 | 4 | — | 12 |
| Safety & Construction | 2 | (1) | 6 | — | 7 | 1 | 2 | 4 | — | 7 |
| Total | 5% | (1)% | 5% | 1% | 10% | 4% | 2% | 4% | 1% | 11% |
| U.S. & Canada | 5% | —% | 2% | 1% | 8% | 3% | —% | 1% | 1% | 5% |
| EMEA | 7 | (1) | 2 | 1 | 9 | 5 | 6 | 4 | 1 | 16 |
| Asia Pacific | 4 | (1) | 11 | 1 | 15 | 3 | 1 | 13 | — | 17 |
| Latin America | 6 | (5) | 10 | (2) | 9 | 6 | (2) | 2 | — | 6 |
| Total | 5% | (1)% | 5% | 1% | 10% | 4% | 2% | 4% | 1% | 11% |

1\. Pro forma net sales for Agriculture excludes sales related to the November 30, 2017, divestiture of the DAS Divested Ag Business for the period January 1, 2017 through August 31, 2017. Sales for the month of September 2017 are included in Portfolio & Other. Pro forma net sales for Packaging & Specialty Plastics excludes sales related to the September 1, 2017, divestiture of the EAA Business for the period January 1, 2017 through August 31, 2017. Portfolio & Other includes sales for the acquisition of the H&N Business acquired on November 1, 2017, impacting Nutrition & Biosciences. Portfolio & Other also reflects the following divestitures: SKC Haas Display Films group of companies (divested June 30, 2017) and the authentication business (divested on January 6, 2017), both impacting Electronics & Imaging; and, the divestiture of the global food safety diagnostic business (divested February 28, 2017), impacting Nutrition & Biosciences.

The Company reported net sales in the third quarter of 2018 of $20.1 billion, up 10 percent from pro forma net sales of $18.3 billion in the third quarter of 2017, with increases across all geographic regions and segments, except Electronics & Imaging which was flat. Double-digit net sales increases were reported in Industrial Intermediates & Infrastructure (up 18 percent), Nutrition & Biosciences (up 14 percent), Packaging & Specialty Plastics and Performance Materials & Coatings (both up 11 percent), and Asia Pacific (up 15 percent). Local price was up 5 percent compared with pro forma results in the same period last year with increases in all geographic regions, in response to higher feedstock and raw material costs. Local price increased across most segments, except Electronics & Imaging (down 1 percent), including a double-digit increase in Performance Materials & Coatings (up 13 percent). Volume increased 5 percent compared with pro forma results in the same period last year, with gains in all geographic regions and segments, except Performance Materials & Coatings (down 1 percent), including double-digit increases in Industrial Intermediates & Infrastructure (up 14 percent), Asia Pacific (up 11 percent), and Latin America (up 10 percent). Currency was down 1 percent compared with the same period last year, driven primarily by Latin America (down 5 percent).

Net sales for the first nine months of 2018 were $65.9 billion, up 11 percent from pro forma net sales of $59.5 billion in the same period last year, with increases across most segments and all geographic regions. Double-digit net sales increases were reported in Industrial Intermediates & Infrastructure (up 26 percent), Nutrition & Biosciences (up 18 percent), Performance Materials & Coatings (up 13 percent), Packaging & Specialty Plastics and Transportation & Advanced Polymers (both up 12 percent). These increases were partially offset by declines in Agriculture and Electronics & Imaging (both down 1 percent). Net sales increased in Asia Pacific (up 17 percent), EMEA (up 16 percent), Latin America (up 6 percent) and U.S. & Canada (up 5 percent). Volume increased 4 percent compared with pro forma results in the same period last year, as increases in Industrial Intermediates &

Infrastructure (up 16 percent), Packaging & Specialty Plastics (up 7 percent), Nutrition & Biosciences, Safety & Construction and Transportation & Advanced Polymers (all up 4 percent) and Electronics & Imaging (up 1 percent) more than offset a decline in Agriculture (down 4 percent). Performance Materials & Coatings volume was flat. Volume increased in all geographic regions, including a double-digit increase in Asia Pacific (up 13 percent). Local price was up 4 percent compared with pro forma results in the same period last year with increases in all geographic regions, driven by pricing initiatives in response to higher feedstock and raw material costs. Local price increased across most segments, including double-digit increases in Performance Materials & Coatings (up 11 percent). Local price in Nutrition & Biosciences and Electronics & Imaging was flat. Currency was up 2 percent compared with the same period last year, driven primarily by EMEA (up 6 percent).

### Cost of Sales

COS was $15.5 billion in the third quarter of 2018, up from $12.2 billion in the third quarter of 2017. The increase was primarily due to the Merger, increased sales volume, which reflected additional capacity from U.S. Gulf Coast growth projects and increased supply from Sadara, higher feedstock and other raw material costs, and higher planned maintenance turnaround costs, which more than offset lower commissioning expenses related to U.S. Gulf Coast growth projects and cost synergies. COS in the third quarter of 2018 was also negatively impacted by a $109 million charge for the fair value step-up in DuPont's inventories as a result of the Merger (related to Agriculture). COS in the third quarter of 2017 was negatively impacted by a $360 million charge for the fair value step-up in inventories assumed in the Merger and related to Agriculture ($82 million), Packaging & Specialty Plastics ($28 million), Electronics & Imaging ($47 million), Nutrition & Biosciences ($104 million), Transportation & Advanced Polymers ($67 million) and Safety & Construction ($32 million), and an $8 million charge for transactions costs and productivity actions (related to Corporate).

For the first nine months of 2018, COS was $49.8 billion, up from $33.1 billion in the first nine months of 2017. The increase was primarily due to the Merger, higher sales volume, higher feedstock and other raw material costs, increased costs from planned maintenance turnaround activity and unplanned events, which more than offset lower commissioning expenses related to U.S. Gulf Coast growth projects and cost synergies. COS in the first nine months of 2018 was negatively impacted by a $1,494 million charge for the fair value step-up in DuPont's inventories as a result of the Merger and the acquisition of the H&N Business, related to Agriculture ($1,424 million), Nutrition & Biosciences ($67 million), Packaging & Specialty Plastics ($2 million) and Safety & Construction ($1 million). In addition to the items previously discussed, in the first nine months of 2017, COS was negatively impacted by a $41 million charge for transaction costs and productivity actions (related to Corporate).

### Research and Development Expenses

R&D expenses totaled $740 million in the third quarter of 2018, up from $528 million in the third quarter of 2017. For the first nine months of 2018, R&D expenses totaled $2,311 million, up from $1,355 million in the first nine months of 2017. R&D expenses increased primarily due to the Merger.

### Selling, General and Administrative Expenses

SG&A expenses were $1,496 million in the third quarter of 2018, up from $1,001 million in the third quarter of 2017. For the first nine months of 2018, SG&A expenses totaled $5,143 million, up from $2,480 million in the first nine months of 2017. SG&A expenses increased primarily due to the Merger.

### Amortization of Intangibles

Amortization of intangibles was $462 million in the third quarter of 2018, up from $244 million in the third quarter of 2017. In the first nine months of 2018, amortization of intangibles was $1,424 million, up from $556 million in the same period last year. The increase in amortization is primarily due to an increase in intangible assets as a result of the Merger. See Note 10 to the Consolidated Financial Statements for additional information on intangible assets.

### Restructuring and Asset Related Charges - Net

#### DowDuPont Cost Synergy Program

In September and November 2017, DowDuPont approved post-merger restructuring actions under the Synergy Program, adopted by the DowDuPont Board of Directors. The plan is designed to integrate and optimize the organization following the Merger and in preparation for the Intended Business Separations. Based on all actions approved to date under the Synergy Program, the Company expects to record total pretax restructuring charges of approximately $2 billion, comprised of approximately $875 million to $975 million of severance and related benefit costs; $400 million to $615 million of asset write-downs and write-offs; and $400 million to $450 million of costs associated with exit and disposal activities.

As a result of these actions, the Company recorded pretax restructuring charges of $179 million for the three and nine months ended September 30, 2017, comprised of severance and related benefit costs. For the three months ended September 30, 2018, the Company recorded pretax restructuring charges of $162 million, consisting of severance and related benefit costs of $67 million, asset write-downs and write-offs of $86 million and costs associated with exit and disposal activities of $9 million. For the nine months ended September 30, 2018, the Company recorded pretax restructuring charges of $604 million, consisting of severance and related benefit costs of $361 million, asset write-downs and write-offs of $167 million and costs associated with exit and disposal activities of $76 million. The restructuring charges for the nine months ended September 30, 2018 were related to each segment as follows: $183 million in Agriculture, $21 million in Safety & Construction, $11 million in Industrial Intermediates & Infrastructure, $7 million in Packaging & Specialty Plastics, $2 million in Electronics & Imaging, $381 million in Corporate and a benefit of $1 million in Transportation & Advanced Polymers. The Company expects to record additional restructuring charges in 2018 and 2019 and expects the Synergy Program to be completed by the end of 2019.

#### Dow 2016 Restructuring Plan

The 2016 restructuring activities were substantially complete at June 30, 2018, with remaining liabilities for severance and related benefit costs and costs associated with exit and disposal activities to be settled over time. See Note 5 to the Consolidated Financial Statements for details on the Company's restructuring activities.

#### Asset Impairments

During the three months ended September 30, 2018, the Company recognized an $85 million pretax impairment charge in “Restructuring and asset related charges - net” in the consolidated statements of income related to certain in-process research and development (“IPR&D") assets related to the Agriculture segment.

In addition, based on updated projections for the Company’s equity method investments in joint ventures in China related to the Agriculture segment, management determined the fair value of the equity method investments was below the carrying value and had no expectation the fair value will be recovered due to the continuing unfavorable regulatory environment, including lack of intellectual property protection, uncertain product registration timing and limited freedom to operate. As a result, management concluded the impairment is other than temporary and recorded an impairment charge of $41 million in “Restructuring and asset related charges - net” in the consolidated statements of income. See Notes 5, 10 and 19 to the Consolidated Financial Statements for additional information.

### Integration and Separation Costs

Integration and separation costs, which reflect costs related to the Merger and the ownership restructure of Dow Silicones, as well as post-Merger integration and Intended Business Separation activities, were $666 million in the third quarter of 2018, up from $354 million in the third quarter of 2017. In the first nine months of 2018, integration and separation costs were $1,681 million, up from $599 million in the same period last year. Integration and separation costs are related to the Corporate segment.

### Equity in Earnings of Nonconsolidated Affiliates

The Company's share of the earnings of nonconsolidated affiliates was $178 million in the third quarter of 2018, up from $152 million in the third quarter of 2017, as higher earnings from the Kuwait joint ventures were partially offset by lower equity earnings from the Thai joint ventures. In the first nine months of 2018, the Company's share of the earnings of nonconsolidated affiliates was $685 million, up from $402 million in the first nine months of 2017, as higher earnings from the Kuwait joint ventures and lower equity losses from Sadara were partially offset by lower equity earnings from the Thai joint ventures and the HSC Group, which reflected customer settlements in the first quarter of 2017 related to long-term polysilicon sales agreements.

### Sundry Income (Expense) - Net

Sundry income (expense) – net includes a variety of income and expense items such as foreign currency exchange gains or losses, interest income, dividends from investments, gains and losses on sales of investments and assets, non-operating pension and other postretirement benefit plan credits or costs, and certain litigation matters. Sundry income (expense) – net in the third quarter of 2018 was income of $47 million, compared with income of $394 million in the third quarter of 2017. The third quarter of 2018 included income related to non-operating pension and other postretirement benefit plans and interest income. These gains more than offset foreign currency exchange losses. The third quarter of 2017 included a $227 million gain from Dow's divestiture of the EAA Business (related to Packaging & Specialty Plastics) and foreign currency exchange gains.

In the first nine months of 2018, sundry income (expense) - net was income of $340 million compared with income of $272 million in the first nine months of 2017. In addition to the amounts previously discussed, the first nine months of 2018 included gains on sales of investments and other assets, including a $20 million gain for post-closing adjustments on Dow's sale of its equity interest in MEGlobal (related to Industrial Intermediates & Infrastructure) and a $24 million gain related to Agriculture asset sales. These gains more than offset foreign currency exchange losses, including a $50 million foreign exchange loss related to adjustments to foreign currency exchange contracts for the change in the U.S. tax rate (related to Corporate), and a $47 million loss for adjustments related to the Dow Silicones ownership restructure ($27 million related to Electronics & Imaging and $20 million related to Performance Materials & Coatings). The first nine months of 2017 included the amounts previously discussed, a $469 million loss related to the Dow AgroSciences arbitration matter with Bayer CropScience (related to Agriculture), a $137 million gain related to the Nova patent infringement award (related to Packaging & Specialty Plastics), and gains on sales of investments and other assets. See Notes 1, 2, 3, 6, 13 and 16 to the Consolidated Financial Statements for additional information.

### Interest Expense and Amortization of Debt Discount

Interest expense and amortization of debt discount was $362 million in the third quarter of 2018, up from $283 million in the third quarter of 2017. Interest expense and amortization of debt discount was $1,072 million for the first nine months of 2018, up from $728 million in the same period last year. The increase primarily reflects debt assumed in the Merger as well as lower capitalized interest.

### Provision for Income Taxes on Continuing Operations

The Company's effective tax rate fluctuates based on, among other factors, where income is earned, reinvestment assertions regarding foreign income and the level of income relative to tax credits available. The Company's tax rate is also influenced by the level of equity earnings, since most of the earnings from the Company's equity method investments are taxed at the joint venture level.

On December 22, 2017, the Tax Cuts and Jobs Act ("The Act") was enacted. The Act reduces the U.S. federal corporate income tax rate from 35 percent to 21 percent, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously deferred, creates new provisions related to foreign sourced earnings, eliminates the domestic manufacturing deduction and moves towards a territorial system. The Company recorded adjustments related to The Act in the three and nine months ended September 30, 2018, which resulted in benefits of $116 million and $38 million, respectively, to "Provision for income taxes on continuing operations."

The effective tax rate for the third quarter of 2018 was 37.4 percent, compared with an effective tax rate of 50.8 percent for the third quarter of 2017. The tax rate in the third quarter of 2018 was unfavorably impacted by a charge associated with a valuation allowance against the net deferred tax asset position of a DuPont legal entity in Brazil, costs associated with the Merger (including a $61 million net tax cost on repatriation activities to facilitate the Intended Business Separations), the tax impact of certain net exchange losses recognized on the remeasurement of the net monetary asset positions which were not deductible in their local jurisdictions, non-deductible restructuring costs, and certain provisions in The Act related to the taxability of foreign earnings and a tax charge related to an internal entity restructuring associated with the Intended Business Separations. The tax rate in the third quarter of 2018 was favorably impacted by the reduced U.S. federal corporate tax rate as well as the effective tax rate impacts related to the non-deductible amortization of the fair value step-up in DuPont’s inventories as a result of the Merger. Discretionary pension contributions to the U.S. plans, made in the third quarter of 2018 and deducted on 2017 tax returns, resulted in a tax benefit of $154 million associated with the reversal of a portion of the U.S. federal deferred tax remeasurement associated with The Act, offset partially by a tax charge of $27 million related to the reduction of a tax benefit recorded in 2017. The tax rate for the third quarter of 2017 was primarily impacted by a $267 million tax charge related to changes in tax attributes in the United States and Germany as a result of the Merger.

For the first nine months of 2018, the effective tax rate was 26.7 percent, compared with 30.5 percent for the first nine months of 2017. In addition to the items previously discussed, the tax rate for the first nine months of 2018 was favorably impacted by tax benefits related to the issuance of stock-based compensation. The tax rate for the first nine months of 2017, in addition to the items previously discussed, reflected a tax benefit from the Bayer CropScience arbitration matter and the adoption of Accounting Standards Update ("ASU") 2016-09, which resulted in the recognition of excess tax benefits related to equity compensation in the provision for income taxes. See Notes 7 and 13 to the Consolidated Financial Statements for additional information.

### Net Income Attributable to Noncontrolling Interests

Net income attributable to noncontrolling interests was $38 million in the third quarter of 2018, up from $20 million in the third quarter of 2017. For the first nine months of 2018, net income attributable to noncontrolling interests was $117 million, compared with $85 million for the same period last year.

### Net Income Available for DowDuPont Inc. Common Stockholders

Net income available for common stockholders was $497 million, or $0.21 per share, in the third quarter of 2018, compared with $514 million, or $0.32 per share, in the third quarter of 2017. Net income available for common stockholders in the first nine months of 2018 was $3,369 million or $1.44 per share, compared with $2,723 million, or $2.01 per share, in the same period of 2017. See Note 8 to the Consolidated Financial Statements for details on the Company's earnings per share calculations.

### SUPPLEMENTAL UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION

The following supplemental unaudited pro forma combined statements of income (the "unaudited pro forma income statements") for DowDuPont are presented to illustrate the estimated effects of the Merger, assuming that the Merger had been consummated on January 1, 2016. Activity for the three and nine months ended September 30, 2017, was prepared on a pro forma basis (the “unaudited pro forma information”). The unaudited pro forma information was prepared in accordance with Article 11 of Regulation S-X. Pro forma adjustments have been made for (1) the preliminary purchase accounting impact, (2) accounting policy alignment, (3) the elimination of the effect of events that are directly attributable to the Merger Agreement (e.g., one-time transaction costs), (4) the elimination of the impact of transactions between Dow and DuPont, and (5) the elimination of the effect of consummated divestitures required as a condition of approval for the Merger. Events that are not expected to have a continuing impact on the combined results (e.g., inventory step-up costs) are excluded from the unaudited pro forma information. The unaudited pro forma information does not reflect restructuring or integration activities or other costs following the Merger that may be incurred to achieve cost or growth synergies of DowDuPont. The unaudited pro forma income statement provides shareholders with summary financial information and historical data that is on a basis consistent with how DowDuPont reports current financial information.

The Merger was accounted for under Accounting Standards Codification ("ASC") Topic 805, "Business Combinations" ("ASC 805"), under which Dow was designated as the accounting acquirer in the Merger for accounting purposes. Under ASC 805, Dow accounted for the transaction by using Dow historical financial information and accounting policies and adding the assets and liabilities of DuPont as of August 31, 2017 (the "Merger Date") at their respective fair values. The assets and liabilities of DuPont were measured based on various preliminary estimates at the Merger Date using assumptions that DowDuPont believes are reasonable based on information that was currently available. The fair value estimates reflected in the unaudited pro forma information are based on those used in the Current Report on Form 8-K/A filed with the SEC on October 26, 2017, and subsequent measurement period adjustments are not reflected.

The unaudited pro forma income statements have been presented for informational purposes only and are not necessarily indicative of what DowDuPont’s results of operations actually would have been had the Merger been completed on January 1, 2016. In addition, the unaudited pro forma income statements do not purport to project the future operating results of the Company. The unaudited pro forma income statements were based on and should be read in conjunction with the separate historical financial statements and accompanying notes contained in each of the Dow and DuPont Quarterly Reports on Form 10-Q for the quarter ended September 30, 2017. See Notes 1 and 3 to the Consolidated Financial Statements for additional information.

*Unaudited Pro Forma Combined Statement of Income*

*Three Months Ended Sep 30, 2017*

*In millions, except per share amounts*

| Adjustments DWDP 1, 2 Historical DuPont 2, 3 | Reclass 2, 4 | Divestitures 5 | Pro Forma 6 | Pro Forma |
| --- | ---: | ---: | ---: | ---: |
| Net sales $15,354 $3,182 | $11 | $(225) | $(37) | $18,285 |
| Cost of sales 12,186 2,016 | 115 | (106) | 13 | 14,224 |
| Other operating charges — 141 | (141) | — | — | — |
| Research and development expenses 528 291 | (7) | (26) | 5 | 791 |
| Selling, general and administrative expenses 1,001 822 | (217) | (41) | 7 | 1,572 |
| Other (loss) income, net — (183) | 183 | — | — | — |
| Amortization of intangibles 244 — | 31 | — | 148 | 423 |
| Restructuring and asset related charges (credits) - net 179 11 | — | — | (10) | 180 |
| Integration and separation costs 354 — | 219 | (9) | (105) | 459 |
| Equity in earnings of nonconsolidated affiliates 152 — | 13 | — | (4) | 161 |
| Sundry income (expense) - net 394 — | (205) | (1) | — | 188 |
| Interest expense and amortization of debt discount 283 71 | — | — | (20) | 334 |
| Income (Loss) from continuing operations before income taxes 1,125 (353) | 2 | (44) | (79) | 651 |
| Provision (Credit) for income taxes on continuing operations 571 (124) | 2 | (10) | (47) | 392 |
| Income (Loss) from continuing operations, net of tax 554 (229) | — | (34) | (32) | 259 |
| Net income attributable to noncontrolling interests 20 5 | — | — | 2 | 27 |
| Net income (loss) from continuing operations attributable to DowDuPont Inc. 534 (234) | — | (34) | (34) | 232 |
| Preferred stock dividends — 2 | — | — | (2) | — |
| Net income (loss) from continuing operations available for DowDuPont Inc. common stockholders $534 $(236) | $— | $(34) | $(32) | $232 |
| Per common share data: |  |  |  |  |
| Earnings per common share from continuing operations - basic |  |  |  | $0.10 |
| Earnings per common share from continuing operations - diluted |  |  |  | $0.10 |
| Weighted-average common shares outstanding - basic |  |  |  | 2,328.0 |
| Weighted-average common shares outstanding - diluted |  |  |  | 2,349.7 |

1\. See the U.S. GAAP consolidated statements of income.

2\. Amounts have been updated to reflect certain reclassifications required under ASU 2017-07, "Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which was adopted on January 1, 2018, and required retrospective application.

3\. Reflects DuPont activity for the period from July 1, 2017 to August 31, 2017.

4\. Certain reclassifications were made to conform with the presentation used for DowDuPont. The reclassifications are consistent with those identified and disclosed in the Current Report on Form 8-K/A filed with the SEC on October 26, 2017.

5\. Includes the following divestitures agreed to with certain regulatory agencies as a condition of approval for the Merger: Dow’s EAA Business; the DAS Divested Ag Business; and DuPont’s cereal broadleaf herbicides and chewing insecticides portfolio as well as its crop protection research and development pipeline and organization. For additional information regarding these divestitures, see Note 4 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

6\. Certain pro forma adjustments were made to illustrate the estimated effects of the Merger, assuming that the Merger had been consummated on January 1, 2016. The pro forma adjustments are consistent with those identified and disclosed in the Company's Current Report on Form 8-K/A filed with the SEC on October 26, 2017.

*Unaudited Pro Forma Combined Statement of Income*

*Nine Months Ended Sep 30, 2017*

*In millions, except per share amounts*

| Adjustments DWDP 1, 2 Historical DuPont 2, 3 | Reclass 2, 4 | Divestitures 5 | Pro Forma 6 | Pro Forma |
| --- | ---: | ---: | ---: | ---: |
| Net sales $42,418 $18,349 | $84 | $(1,219) | $(163) | $59,469 |
| Cost of sales 33,141 10,464 | 387 | (523) | 65 | 43,534 |
| Other operating charges — 521 | (521) | — | — | — |
| Research and development expenses 1,355 1,117 | (27) | (104) | 19 | 2,360 |
| Selling, general and administrative expenses 2,480 3,368 | (583) | (143) | 29 | 5,151 |
| Other (loss) income, net — (106) | 106 | — | — | — |
| Amortization of intangibles 556 — | 139 | — | 591 | 1,286 |
| Restructuring and asset related charges (credits) - net 166 323 | — | — | (10) | 479 |
| Integration and separation costs 599 — | 605 | (24) | (183) | 997 |
| Equity in earnings of nonconsolidated affiliates 402 — | 55 | — | (15) | 442 |
| Sundry income (expense) - net 272 — | (278) | (12) | — | (18) |
| Interest expense and amortization of debt discount 728 254 | — | — | (80) | 902 |
| Income from continuing operations before income taxes 4,067 2,196 | (33) | (437) | (609) | 5,184 |
| Provision for income taxes on continuing operations 1,239 228 | (33) | (88) | (233) | 1,113 |
| Income from continuing operations, net of tax 2,828 1,968 | — | (349) | (376) | 4,071 |
| Net income attributable to noncontrolling interests 85 20 | — | — | 7 | 112 |
| Net income from continuing operations attributable to DowDuPont Inc. 2,743 1,948 | — | (349) | (383) | 3,959 |
| Preferred stock dividends — 7 | — | — | (7) | — |
| Net income from continuing operations available for DowDuPont Inc. common stockholders $2,743 $1,941 | $— | $(349) | $(376) | $3,959 |
| Per common share data: |  |  |  |  |
| Earnings per common share from continuing operations - basic |  |  |  | $1.70 |
| Earnings per common share from continuing operations - diluted |  |  |  | $1.68 |
| Weighted-average common shares outstanding - basic |  |  |  | 2,322.9 |
| Weighted-average common shares outstanding - diluted |  |  |  | 2,346.2 |

1\. See the U.S. GAAP consolidated statements of income.

2\. Amounts have been updated to reflect certain reclassifications required under ASU 2017-07, "Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost," which was adopted on January 1, 2018, and required retrospective application.

3\. Reflects DuPont activity for the period from January 1, 2017 to August 31, 2017.

4\. Certain reclassifications were made to conform with the presentation used for DowDuPont. The reclassifications are consistent with those identified and disclosed in the Current Report on Form 8-K/A filed with the SEC on October 26, 2017.

5\. Includes the following divestitures agreed to with certain regulatory agencies as a condition of approval for the Merger: Dow’s EAA Business; the DAS Divested Ag Business; and DuPont’s cereal broadleaf herbicides and chewing insecticides portfolio as well as its crop protection research and development pipeline and organization. For additional information regarding these divestitures, see Note 4 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

6\. Certain pro forma adjustments were made to illustrate the estimated effects of the Merger, assuming that the Merger had been consummated on January 1, 2016. The pro forma adjustments are consistent with those identified and disclosed in the Company's Current Report on Form 8-K/A filed with the SEC on October 26, 2017.

### OUTLOOK

Global demand for DowDuPont's products remains strong, supported by solid fundamentals, including business investment, manufacturing output, job growth and wage increases. Going forward, DowDuPont remains well positioned to continue to drive top-line gains from above-GDP demand growth for the Company's products and new product launches, while further delivering productivity and cost synergy savings.

#### Impact From Recently Enacted Tariffs

Certain countries where the Company’s products are manufactured, distributed or sold have recently enacted tariffs on certain products. The Company has analyzed the direct impact from the enacted tariffs and does not expect them to have a material impact on results of operations in 2018. The Company is taking actions to mitigate the impact by leveraging its global asset base to adjust its product and raw material flows.

### SEGMENT RESULTS

Beginning in the third quarter of 2018, DowDuPont realigned the following joint ventures, global businesses and product lines in preparation for the Intended Business Separations:

- Realignment of the HSC Group joint ventures (DC HSC Holdings LLC and Hemlock Semiconductor L.L.C.) from the Consumer Solutions global business in the Performance Materials & Coatings reportable segment to the Electronics & Imaging reportable segment.
- Realignment of certain cellulosics product lines from the Nutrition & Health operating segment in the Nutrition & Biosciences reportable segment to the Consumer Solutions global business in the Performance Materials & Coatings reportable segment.
- Certain roofing products were realigned from the Building Solutions product line in the Safety & Construction reportable segment to Corporate.
- Realignment of the previously divested Epoxy and Chlorinated Organics global businesses from the Industrial Intermediates & Infrastructure reportable segment to Corporate.
- In addition, the following realignments within the Industrial Intermediates & Infrastructure reportable segment were made, which had no effect on the segment results:
- The Construction Chemicals global business was combined with the Polyurethanes & CAV global business.
- Certain product lines associated with the oil and gas industry were realigned from the Industrial Solutions global business to the Polyurethanes & CAV global business.

The reporting changes have been retrospectively reflected in the following discussion of segment results for all periods presented.

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA (for the three and nine months ended September 30, 2018) and pro forma Operating EBITDA (for the three and nine months ended September 30, 2017) as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization and foreign exchange gains (losses), excluding the impact of significant items. Pro forma Operating EBITDA is defined as pro forma earnings (i.e., pro forma “Income from continuing operations before income taxes") before interest, depreciation, amortization and foreign exchange gains (losses), excluding the impact of adjusted significant items. Reconciliations of these measures can be found in Note 21 to the Consolidated Financial Statements. The Company also presents pro forma net sales for the three and nine months ended September 30, 2017, as it is included in management’s measure of segment performance and is regularly reviewed by the CODM. Prior year data has been updated to conform with the current year presentation.

Pro forma adjustments used in the calculation of pro forma net sales and pro forma Operating EBITDA were determined in accordance with Article 11 of Regulation S-X and were based on the historical consolidated financial statements of Dow and DuPont, adjusted to give effect to the Merger as if it had been consummated on January 1, 2016. For additional information on the pro forma adjustments made, see Supplemental Unaudited Pro Forma Combined Financial Information in the preceding section.

### AGRICULTURE

The Agriculture segment leverages the Company’s technology, customer relationships and industry knowledge to improve the quantity, quality and safety of the global food supply and the global production agriculture industry. Land available for worldwide agricultural production is increasingly limited so production growth will need to be achieved principally through improving crop yields and productivity. The segment’s two global businesses, Seed and Crop Protection, deliver a broad portfolio of products and services that are specifically targeted to achieve gains in crop yields and productivity, including well-established brands of seed products, crop chemicals, seed treatment, agronomy and digital services. R&D focuses on leveraging germplasm and plant science technology to increase farmer productivity and to enhance the value of grains and oilseeds through improved seed traits, superior seed germplasm and effective use of crop protection solutions.

*In millions*

| Agriculture | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,946 | $1,532 | $11,484 | $4,729 |
| Pro forma net sales |  | $1,911 |  | $11,555 |
| Operating EBITDA | $(104) |  | $2,472 |  |
| Pro forma Operating EBITDA |  | $(239) |  | $2,387 |
| Equity losses | $(3) | $(5) | $(1) | $(1) |

| Agriculture Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Sep 30, 2018 | Nine Months Ended Sep 30, 2018 |
| --- | ---: | ---: |
| Local price & product mix | 3% | 2% |
| Currency | (5) | — |
| Volume | 3 | (2) |
| Portfolio & other | 26 | 143 |
| Total | 27% | 143% |
| Change in Net Sales in Current Period from Pro Forma Net Sales in Prior Period due to: |  |  |
| Local price & product mix | 3% | 3% |
| Currency | (6) | 1 |
| Volume | 8 | (4) |
| Portfolio & other | (3) | (1) |
| Total | 2% | (1)% |

Agriculture net sales were $1,946 million in the third quarter of 2018, up from $1,532 million in the third quarter of 2017. Net sales in the third quarter of 2018 were up 2 percent from pro forma net sales of $1,911 million in the third quarter of 2017. The increase was primarily due to 8 percent growth in volume and a 3 percent increase in local price, partially offset by a 3 percent decrease in portfolio and a 6 percent decrease in currency.

Volume increased primarily in Crop Protection due to growth in fungicides and insecticides driven by new product launches including Picoxy-based products in Latin America and PYRAXALTTM in Asia Pacific, as well as growth in seed applied technologies and improved channel inventory levels in Latin America. In Seeds, increased volume was due to gains in corn seeds in Latin America, partially driven by an early start to the selling season in Latin America. Unfavorable currency impacts primarily due to the Brazilian real were partially offset by increases in local price in Crop Protection to offset currency pressure. The portfolio loss reflected the inclusion of one month of the Dow AgroSciences corn seed remedy in the 2017 results.

Operating EBITDA was a loss of $104 million in the third quarter of 2018, compared with a pro forma Operating EBITDA loss of $239 million in the same quarter last year. Cost synergies, volume growth, lower performance-based compensation and lower pension/OPEB costs were partially offset by higher raw material costs and increased R&D spend to continue advancing the pipeline.

Agriculture net sales were $11,484 million for the first nine months of 2018, up from $4,729 million in the first nine months of 2017. Net sales in the first nine months of 2018 were down 1 percent from pro forma net sales of $11,555 million in the first nine months of 2017. Net sales declined as a 4 percent decrease in volume and a 1 percent decline due to portfolio was partially offset by a 3 percent increase in local price and a 1 percent benefit from currency.

The decline in volume was driven by lower planted area in U.S. & Canada partially offset by new product launches in Asia Pacific. Increased volume in Latin America for the start of the summer season was offset by decreases in Seeds in the region due to lower sales in the Brazil safrinha season. The increase in local price was driven by favorable mix in U.S. & Canada and increases in Crop Protection pricing in Latin America to offset currency pressure. The portfolio loss reflected the inclusion of one month of the Dow AgroSciences corn seed remedy in 2017 results.

Operating EBITDA was $2,472 million in the first nine months of 2018, up 4 percent from pro forma Operating EBITDA of $2,387 million in the first nine months of 2017. Cost synergies, lower pension/OPEB costs and the favorable impact of currency were partially offset by lower volume, higher royalty expense and investments to support new product launches and digital platforms.

### PERFORMANCE MATERIALS & COATINGS

The Performance Materials & Coatings segment consists of two global businesses: Coatings & Performance Monomers and Consumer Solutions. Using silicones, acrylics and cellulosics-based technology platforms, these businesses serve the needs of the coatings, home care, personal care, appliance and industrial end-markets. The segment has broad geographic reach with R&D and manufacturing facilities located in key geographic regions.

*In millions*

| Performance Materials & Coatings | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $2,476 | $2,234 | $7,379 | $6,599 |
| Pro forma net sales |  | $2,227 |  | $6,558 |
| Operating EBITDA | $628 |  | $1,749 |  |
| Pro forma Operating EBITDA |  | $460 |  | $1,374 |
| Equity earnings | $3 | $10 | $4 | $32 |

| Performance Materials & Coatings Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Sep 30, 2018 | Nine Months Ended Sep 30, 2018 |
| --- | ---: | ---: |
| Local price & product mix | 13% | 11% |
| Currency | (1) | 2 |
| Volume | (1) | (1) |
| Portfolio & other | — | — |
| Total | 11% | 12% |
| Change in Net Sales in Current Period from Pro Forma Net Sales in Prior Period due to: |  |  |
| Local price & product mix | 13% | 11% |
| Currency | (1) | 2 |
| Volume | (1) | — |
| Portfolio & other | — | — |
| Total | 11% | 13% |

Performance Materials & Coatings net sales were $2,476 million in the third quarter of 2018, up from net sales of $2,234 million in the third quarter of 2017. Net sales increased 11 percent compared with pro forma net sales of $2,227 million in the same quarter last year, with local price up 13 percent and currency and volume each down 1 percent. Local price increased in all geographic regions and in both businesses. Local price increased in Consumer Solutions primarily due to disciplined price/volume management in upstream silicone intermediates. Coatings & Performance Monomers local price increased in response to higher feedstock and raw material costs. Volume decreased in Consumer Solutions in all geographic regions, except Latin America, due to capacity constraints and a strategic focus on products that maximize margin. Volume increased in Coatings & Performance Monomers in all geographic regions, except EMEA, as a result of demand recovery in architectural and industrial coatings.

Operating EBITDA was $628 million in the third quarter of 2018, up 37 percent from pro forma Operating EBITDA of $460 million in the third quarter of 2017, as higher selling prices and cost synergies more than offset increased feedstock and other raw material costs.

Performance Materials & Coatings net sales for the first nine months of 2018 were $7,379 million, up from net sales of $6,599 million in the first nine months of 2017. Net sales increased 13 percent compared with pro forma net sales of $6,558 million in the first nine months of 2017, with local price up 11 percent and a benefit from currency of 2 percent, while volume was flat. Local price increased in both businesses and all geographic regions. Volume was flat in Consumer Solutions and decreased slightly in Coatings & Performance Monomers. Volume decreased in EMEA and U.S. & Canada, more than offsetting increased volume in Asia Pacific and Latin America.

Operating EBITDA was $1,749 million for the first nine months of 2018, up 27 percent from pro forma Operating EBITDA of $1,374 million in the first nine months of 2017, as higher selling prices and cost synergies more than offset increased feedstock and other raw material costs and lower gains from the sales of assets and investments.

### INDUSTRIAL INTERMEDIATES & INFRASTRUCTURE

The Industrial Intermediates & Infrastructure segment consists of two global businesses: Industrial Solutions and Polyurethanes & CAV. These customer-centric global businesses develop and market customized materials using advanced technology and unique chemistries. These businesses serve the needs of market segments as diverse as appliance, coatings, infrastructure, and oil and gas. The segment has broad geographic reach and R&D and manufacturing facilities located in key geographic regions. This segment also includes a portion of the results of EQUATE Petrochemical Company K.S.C.C. ("EQUATE"), The Kuwait Olefins Company K.S.C.C. ("TKOC"), Map Ta Phut Olefins Company Limited and Sadara, all joint ventures of the Company.

Dow is responsible for marketing a majority of Sadara products outside of the Middle East zone through Dow's established sales channels. As part of this arrangement, Dow purchases and sells Sadara products for a marketing fee.

*In millions*

| Industrial Intermediates & Infrastructure | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $3,821 | $3,228 | $11,421 | $9,094 |
| Pro forma net sales |  | $3,226 |  | $9,086 |
| Operating EBITDA | $654 |  | $1,990 |  |
| Pro forma Operating EBITDA |  | $676 |  | $1,605 |
| Equity earnings | $54 | $41 | $299 | $101 |

| Industrial Intermediates & Infrastructure Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Sep 30, 2018 | Nine Months Ended Sep 30, 2018 |
| --- | ---: | ---: |
| Local price & product mix | 5% | 8% |
| Currency | (1) | 2 |
| Volume | 14 | 16 |
| Portfolio & other | — | — |
| Total | 18% | 26% |
| Change in Net Sales in Current Period from Pro Forma Net Sales in Prior Period due to: |  |  |
| Local price & product mix | 5% | 8% |
| Currency | (1) | 2 |
| Volume | 14 | 16 |
| Portfolio & other | — | — |
| Total | 18% | 26% |

Industrial Intermediates & Infrastructure net sales were $3,821 million in the third quarter of 2018, up from net sales of $3,228 million in the third quarter of 2017. Net sales increased 18 percent compared with pro forma net sales of $3,226 million in the same quarter last year, with volume up 14 percent, local price up 5 percent and currency down 1 percent. Volume increased in all businesses and geographic regions. Polyurethanes & CAV reported volume increases in all geographic regions, except Latin America, reflecting growth in EMEA and Asia Pacific from increased supply from Sadara and higher demand for chlor-alkali and vinyl products in EMEA. Industrial Solutions volume increased in all regions driven by increased supply from Sadara and increased demand for industrial specialties, with double-digit growth in intermediates for crop defense, energy heat management and food and feed manufacturing. Local price increased in all businesses and all geographic regions, except Asia Pacific. Local price increases were driven by higher feedstock and other raw material costs, pricing initiatives and strong demand for caustic soda and propylene glycol which more than offset price declines in isocyanates. Currency had a negative impact of 1 percent, primarily in EMEA and Asia Pacific.

Operating EBITDA was $654 million in the third quarter of 2018, down 3 percent compared with pro forma Operating EBITDA of $676 million in the third quarter of 2017. Operating EBITDA decreased as the impact of higher feedstock and other raw material costs, the easing of isocyanate margins, and the impact of an unplanned outage associated with an isocyanates facility in the U.S. Gulf Coast more than offset higher selling prices, cost synergies, demand growth and higher equity earnings from the Kuwait joint ventures.

Industrial Intermediates & Infrastructure net sales for the first nine months of 2018 were $11,421 million, up from net sales of $9,094 million in the first nine months of 2017. Net sales increased 26 percent compared with pro forma net sales of $9,086 million in the first nine months of 2017, with volume up 16 percent, local price up 8 percent and currency up 2 percent. Volume increased in all businesses and geographic regions and local price increased in all businesses and all geographic regions, except Asia Pacific.

Operating EBITDA was $1,990 million for the first nine months of 2018, up 24 percent from pro forma Operating EBITDA of $1,605 million in the first nine months of 2017. Compared with pro forma Operating EBITDA from the same period last year, Operating EBITDA increased as the impact of higher selling prices, the benefit from currency on sales, cost synergies, higher equity earnings from the Kuwait joint ventures and lower equity losses from Sadara more than offset higher feedstock and other raw material costs and the unfavorable impact of currency on costs.

### PACKAGING & SPECIALTY PLASTICS

The Packaging & Specialty Plastics segment is a market-oriented portfolio composed of two global businesses: Hydrocarbons & Energy and Packaging and Specialty Plastics. The segment is advantaged through its low cost position into key feedstocks and broad geographic reach, with manufacturing facilities located in all geographic regions. It also benefits from R&D expertise to deliver leading-edge technology that provides a competitive benefit to customers in food packaging and other high-growth end-use markets like transportation and consumer durables. Taken together, the businesses in this segment represent the world's leading plastics franchise. This segment also includes the results of The Kuwait Styrene Company K.S.C.C. and The SCG-Dow Group, as well as a portion of the results of EQUATE, TKOC, Map Ta Phut Olefins Company Limited and Sadara, all joint ventures of the Company.

Dow is responsible for marketing a majority of Sadara products outside of the Middle East zone through Dow’s established sales channels. As part of this arrangement, Dow purchases and sells Sadara products for a marketing fee.

*In millions*

| Packaging & Specialty Plastics | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $6,119 | $5,260 | $18,228 | $15,364 |
| Pro forma net sales |  | $5,490 |  | $16,300 |
| Operating EBITDA | $1,191 |  | $3,822 |  |
| Pro forma Operating EBITDA |  | $1,147 |  | $3,424 |
| Equity earnings | $83 | $64 | $250 | $130 |

| Packaging & Specialty Plastics Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Sep 30, 2018 | Nine Months Ended Sep 30, 2018 |
| --- | ---: | ---: |
| Local price & product mix | 7% | 4% |
| Currency | — | 2 |
| Volume | 5 | 7 |
| Portfolio & other | 4 | 6 |
| Total | 16% | 19% |
| Change in Net Sales in Current Period from Pro Forma Net Sales in Prior Period due to: |  |  |
| Local price & product mix | 6% | 3% |
| Currency | — | 2 |
| Volume | 5 | 7 |
| Portfolio & other | — | — |
| Total | 11% | 12% |

Packaging & Specialty Plastics net sales were $6,119 million in the third quarter of 2018, up from net sales of $5,260 million in the third quarter of 2017. Net sales increased 11 percent compared with pro forma net sales of $5,490 million in the same quarter last year, with local price up 6 percent and volume up 5 percent. Local price increased across all geographic regions and in both businesses in response to higher feedstock and other raw material costs. Volume increased across all geographic regions and in both businesses supported by new capacity additions on the U.S. Gulf Coast. Packaging and Specialty Plastics volume growth was driven by increases in industrial and consumer packaging, health and hygiene solutions and elastomer applications. Hydrocarbons & Energy volume increased due to higher sales of ethylene and ethylene by-products.

Operating EBITDA was $1,191 million in the third quarter of 2018, up 4 percent from pro forma Operating EBITDA of $1,147 million in the third quarter of 2017. Compared with pro forma Operating EBITDA from the same quarter last year, Operating EBITDA increased as the impact of higher sales volume, reflecting additional capacity from U.S. Gulf Coast growth projects, higher selling prices, cost synergies, higher equity earnings and lower start-up and commissioning costs more than offset higher feedstock and other raw materials costs and increased costs from planned maintenance turnarounds.

Packaging & Specialty Plastics net sales for the first nine months of 2018 were $18,228 million, up from net sales of $15,364 million in the first nine months of 2017. Net sales increased 12 percent compared with pro forma net sales of $16,300 million in the first nine months of 2017, with volume up 7 percent, local price up 3 percent and currency up 2 percent, primarily in EMEA. Volume increased in both businesses and across all geographic regions primarily due to new capacity additions on the U.S. Gulf Coast and increased supply from Sadara. Local price increased in both businesses and across all geographic regions in response to higher feedstock and other raw material costs.

Operating EBITDA was $3,822 million for the first nine months of 2018, up 12 percent from pro forma Operating EBITDA of $3,424 million in the first nine months of 2017. Compared with pro forma Operating EBITDA from the same period last year, Operating EBITDA increased as the impact of higher sales volume, reflecting additional capacity from growth projects, higher selling prices, the benefit from currency on sales, cost synergies, higher equity earnings and lower start-up and commissioning costs more than offset higher feedstock and other raw materials costs, the unfavorable impact of currency on costs, increased costs from planned maintenance turnarounds and the impact of weather-related disruptions on the U.S. Gulf Coast.

### ELECTRONICS & IMAGING

The Electronics & Imaging segment is a leading global supplier of differentiated materials and systems for a broad range of consumer electronics including mobile devices, television monitors, personal computers and electronics used in a variety of industries. The segment is a leading provider of materials and solutions for the fabrication of semiconductors and integrated circuits and also provides innovative metallization processes for metal finishing, decorative, and industrial applications. Electronics & Imaging is a leading global supplier of key materials for the manufacturing of photovoltaics ("PV") and solar cells, including innovative metallization pastes and back sheet materials for the production of solar cells and solar modules and in the advanced printing and packaging graphics industry providing flexographic printing inks, photopolymer plates, and platemaking systems used in digital printing applications for textile, commercial and home-office use. In addition, the segment provides cutting-edge materials for the manufacturing of rigid and flexible displays for liquid crystal displays ("LCD"), advanced-matrix organic light emitting diode ("AMOLED"), and quantum dot ("QD") applications. This segment also includes the results of the HSC Group joint ventures.

*In millions*

| Electronics & Imaging | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,195 | $832 | $3,551 | $2,164 |
| Pro forma net sales |  | $1,197 |  | $3,582 |
| Operating EBITDA | $412 |  | $1,217 |  |
| Pro forma Operating EBITDA |  | $411 |  | $1,259 |
| Equity earnings | $35 | $29 | $124 | $139 |

| Electronics & Imaging Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Sep 30, 2018 | Nine Months Ended Sep 30, 2018 |
| --- | ---: | ---: |
| Local price & product mix | (1)% | —% |
| Currency | — | 1 |
| Volume | 3 | 2 |
| Portfolio & other | 42 | 61 |
| Total | 44% | 64% |
| Change in Net Sales in Current Period from Pro Forma Net Sales in Prior Period due to: |  |  |
| Local price & product mix | (1)% | —% |
| Currency | — | 1 |
| Volume | 1 | 1 |
| Portfolio & other | — | (3) |
| Total | —% | (1)% |

Electronics & Imaging net sales were $1,195 million in the third quarter of 2018, up from $832 million in the third quarter of 2017. Net sales in the third quarter of 2018 were flat with pro forma net sales of $1,197 million in the third quarter of 2017, as volume growth was offset by lower local price.

Volume growth in the segment was driven by continued strength in semiconductor technologies and gains in display & other technologies. Increased semiconductor content in end-use applications drove strong demand in both chemical mechanical planarization (“CMP”) and advanced packaging market segments. Growth in display & other technologies was driven by strong demand in OLEDs, primarily in Asia Pacific. Partially offsetting this growth was a decline in photovoltaic & advanced materials on reduced demand for TEDLAR® film and SOLAMET® paste resulting from revised incentive policies in China.

Operating EBITDA was $412 million in the third quarter of 2018, flat compared with pro forma Operating EBITDA of $411 million in the third quarter of 2017. Cost synergies, volume growth and lower pension/OPEB costs were offset by higher raw material costs, higher costs due to growth investments and lower equity earnings in the third quarter of 2018 as compared with pro forma equity earnings in the third quarter of 2017.

Electronics & Imaging net sales were $3,551 million for the first nine months of 2018, up from $2,164 million in the first nine months of 2017. Net sales for the first nine months of 2018 were down 1 percent from pro forma net sales of $3,582 million in the first nine months of 2017. Net sales declined as 3 percent unfavorable impact from portfolio actions related to the prior year divestiture of the SKC Haas Display Films business, was partially offset by volume growth of 1 percent and a 1 percent benefit from currency.

Volume growth in the segment was driven by gains in semiconductor technologies, interconnect solutions and display & other technologies, primarily in Asia Pacific, partially offset by a decline in photovoltaic & advanced materials.

Operating EBITDA was $1,217 million for the first nine months of 2018, down 3 percent from pro forma Operating EBITDA of $1,259 million for the first nine months of 2017. Cost synergies, lower pension/OPEB costs, volume growth and favorable currency, were more than offset by higher unit costs, lower equity earnings as compared with pro forma equity earnings in the first nine months of 2017 and the absence of a prior-year gain on the sale of a business.

### Updated Outlook

The Operating EBITDA outlook for 2018 is now expected to increase moderately as compared with 2017 pro forma Operating EBITDA, driven by cost synergies, volume growth, lower pension/OPEB costs and higher equity earnings, partially offset by higher raw material costs, the absence of a prior-year gain on the sale of a business and higher costs due to growth investments.

### NUTRITION & BIOSCIENCES

The Nutrition & Biosciences segment is an innovation-driven and customer-focused segment that provides solutions for the global food and beverage, pharma, personal care, energy and animal nutrition markets. The segment consists of two operating segments: Nutrition & Health and Industrial Biosciences. The Nutrition & Health business is one of the world's largest producers of specialty food ingredients, developing and manufacturing solutions for the global food and beverage market. The Nutrition & Health business is also one of the world's largest producers of cellulosic- and alginates-based pharma excipients. The Industrial Biosciences business is an industry pioneer and innovator that works with customers to improve the performance, productivity and sustainability of their products and processes through biotechnology and engineering solutions including enzymes, biomaterials, biocides and antimicrobial solutions and process technology.

*In millions*

| Nutrition & Biosciences | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,678 | $682 | $5,173 | $1,203 |
| Pro forma net sales |  | $1,466 |  | $4,371 |
| Operating EBITDA | $414 |  | $1,265 |  |
| Pro forma Operating EBITDA |  | $312 |  | $944 |
| Equity earnings | $4 | $3 | $12 | $9 |

| Nutrition & Biosciences Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Sep 30, 2018 | Nine Months Ended Sep 30, 2018 |
| --- | ---: | ---: |
| Local price & product mix | 2% | 3% |
| Currency | (2) | — |
| Volume | (4) | — |
| Portfolio & other | 150 | 327 |
| Total | 146% | 330% |
| Change in Net Sales in Current Period from Pro Forma Net Sales in Prior Period due to: |  |  |
| Local price & product mix | 1% | —% |
| Currency | (1) | 2 |
| Volume | 3 | 4 |
| Portfolio & other | 11 | 12 |
| Total | 14% | 18% |

Nutrition & Biosciences net sales were $1,678 million in the third quarter of 2018, up from $682 million in the third quarter of 2017. Net sales in the third quarter of 2018 were up 14 percent from pro forma net sales of $1,466 million in the third quarter of 2017. The increase was primarily due to an 11 percent net benefit from portfolio actions due to the acquisition of FMC’s Health & Nutrition business, 3 percent in volume growth and a 1 percent increase in local price, partially offset by a 1 percent unfavorable impact from currency.

Volume gains in the segment were led by Nutrition & Health on continued growth in probiotics and specialty proteins, primarily in Asia Pacific. Industrial Biosciences volume grew on increased demand for clean technologies due to alkylation and acid equipment sales and in bioactives for home and personal care applications, offset by declines in microbial control solutions and biomaterials.

Operating EBITDA was $414 million in the third quarter of 2018, up 33 percent compared with pro forma Operating EBITDA of $312 million in the third quarter of 2017, driven by a portfolio benefit, cost synergies, volume growth and lower pension/OPEB costs.

Nutrition & Biosciences net sales were $5,173 million for the first nine months of 2018, up from $1,203 million in the first nine months of 2017. Net sales for the first nine months of 2018 were up 18 percent from pro forma net sales of $4,371 million in the first nine months of 2017. The increase was primarily due to a 12 percent net benefit from portfolio actions due to the acquisition of FMC's Health & Nutrition business, 4 percent in volume growth and a 2 percent benefit from currency.

Volume growth in the segment was led by Nutrition & Health on gains in probiotics, specialty proteins and pharmaceutical excipients, driven by demand in Asia Pacific. Industrial Biosciences volume grew on improvement in clean technologies due to alkylation offerings in Asia Pacific and EMEA and acid equipment sales. Demand for bioactives in animal nutrition and home and personal care applications also contributed to volume growth.

Operating EBITDA was $1,265 million for the first nine months of 2018, up 34 percent from pro forma Operating EBITDA of $944 million in the first nine months of 2017, driven by favorable portfolio actions, cost synergies, volume growth and lower pension/OPEB costs, partially offset by higher costs due to growth investments.

### TRANSPORTATION & ADVANCED POLYMERS

The Transportation & Advanced Polymers segment provides high-performance engineering resins, adhesives, lubricants and parts to engineers and designers in the transportation, electronics, medical, industrial and consumer end-markets to enable systems solutions for demanding applications and environments. The segment delivers a broad range of polymer-based high-performance materials in its product portfolio, including elastomers and thermoplastic and thermoset engineering polymers which are used by customers to fabricate components for mechanical, chemical and electrical systems. In addition, the segment produces innovative and differentiated adhesive technologies to meet customer specifications for durability, crash performance, and healthcare applications. Transportation & Advanced Polymers also targets the performance plastics and fluid solutions markets by developing technologies that differentiate customers’ products with improved performance characteristics.

*In millions*

| Transportation & Advanced Polymers | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,408 | $637 | $4,301 | $1,225 |
| Pro forma net sales |  | $1,299 |  | $3,834 |
| Operating EBITDA | $430 |  | $1,313 |  |
| Pro forma Operating EBITDA |  | $325 |  | $954 |
| Equity earnings | $— | $1 | $4 | $1 |

| Transportation & Advanced Polymers Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Sep 30, 2018 | Nine Months Ended Sep 30, 2018 |
| --- | ---: | ---: |
| Local price & product mix | 4% | 3% |
| Currency | (1) | 2 |
| Volume | 1 | 1 |
| Portfolio & other | 117 | 245 |
| Total | 121% | 251% |
| Change in Net Sales in Current Period from Pro Forma Net Sales in Prior Period due to: |  |  |
| Local price & product mix | 6% | 5% |
| Currency | (1) | 3 |
| Volume | 3 | 4 |
| Portfolio & other | — | — |
| Total | 8% | 12% |

Transportation & Advanced Polymers net sales were $1,408 million in the third quarter of 2018, up from $637 million in the third quarter of 2017. Net sales in the third quarter of 2018 were up 8 percent from pro forma net sales of $1,299 million in the third quarter of 2017. The increase was due to a 6 percent increase in local price and 3 percent of volume growth, partially offset by a 1 percent unfavorable impact from currency.

Volume growth in the segment was primarily due to performance solutions, led by growth in VESPEL® high-performance parts in the electronics and aerospace markets, performance resins due to growth in DELRIN® and VAMAC® in the automotive market and in engineering polymers due to growth in ZYTEL® HTN. Broad based volume growth was led by U.S. & Canada and Asia Pacific. The increase in local price, primarily in engineering polymers, was driven by tight polymer supply and higher feedstock costs.

Operating EBITDA was $430 million in the third quarter of 2018, up 32 percent compared with pro forma Operating EBITDA of $325 million in the third quarter of 2017. The increase was driven by higher local selling price, volume gains, lower pension/OPEB costs and cost synergies, partially offset by higher raw material costs.

Transportation & Advanced Polymers net sales were $4,301 million for the first nine months of 2018, up from $1,225 million in the first nine months of 2017. Net sales in the first nine months of 2018 were up 12 percent from pro forma net sales of $3,834 million in the first nine months of 2017. The increase was due to a 5 percent increase in local price, 4 percent of volume growth and a 3 percent benefit from currency.

Volume growth in the segment was primarily due to performance solutions, led by growth in KALREZ® and VESPEL® high-performance parts in the electronics and aerospace markets, performance resins due to growth in DELRIN® and HYTREL® in the automotive market and in engineering polymers due to growth in ZYTEL®. Broad based volume growth was led by Asia Pacific. The increase in local price, primarily in engineering polymers, was driven by tight polymer supply and higher feedstock costs.

Operating EBITDA was $1,313 million for the first nine months of 2018, up 38 percent from pro forma Operating EBITDA of $954 million in the first nine months of 2017 due to price and volume gains, lower pension/OPEB costs, cost synergies and favorable currency, partially offset by higher raw material costs.

### SAFETY & CONSTRUCTION

The Safety & Construction segment is a leading provider of engineered products and integrated systems for a number of industries including construction, worker safety, energy, oil and gas, transportation, medical devices and water purification and separation. The segment satisfies the growing global needs of businesses, governments, and consumers for solutions that make life safer, healthier and better. By uniting market-driven science with the strength of highly regarded brands, the segment strives to bring new products and solutions to solve customers' needs faster, better and more cost effectively. The segment is a leader in safety consulting, selling training products as well as consulting services, to improve the safety, productivity and sustainability of organizations across a range of industries.

*In millions*

| Safety & Construction | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,402 | $792 | $4,112 | $1,716 |
| Pro forma net sales |  | $1,310 |  | $3,852 |
| Operating EBITDA | $389 |  | $1,084 |  |
| Pro forma Operating EBITDA |  | $353 |  | $908 |
| Equity earnings | $6 | $(1) | $19 | $(1) |

| Safety & Construction Percentage change from prior year Change in Net Sales from Prior Period due to: | Three Months Ended Sep 30, 2018 | Nine Months Ended Sep 30, 2018 |
| --- | ---: | ---: |
| Local price & product mix | 2% | 2% |
| Currency | (1) | 1 |
| Volume | 5 | 2 |
| Portfolio & other | 71 | 135 |
| Total | 77% | 140% |
| Change in Net Sales in Current Period from Pro Forma Net Sales in Prior Period due to: |  |  |
| Local price & product mix | 2% | 1% |
| Currency | (1) | 2 |
| Volume | 6 | 4 |
| Portfolio & other | — | — |
| Total | 7% | 7% |

Safety & Construction net sales were $1,402 million in the third quarter of 2018, up from $792 million in the third quarter of 2017. Net sales in the third quarter of 2018 were up 7 percent from pro forma net sales of $1,310 million in the third quarter of 2017 due to 6 percent of volume growth and a 2 percent increase in local price, partially offset by a 1 percent unfavorable impact from currency.

Volume growth in the segment was led by broad-based growth across industrial, life and personal protection, and medical packaging end-markets, resulting in increased sales in aramids of KEVLAR® high-strength materials and NOMEX® thermal-resistant fibers, as well as gains in water solutions and TYVEK® enterprise. These increases were partially offset by declines in construction due to a slowdown in the U.S. residential market. The increase in local price was due to price gains across most businesses.

Operating EBITDA was $389 million in the third quarter of 2018, up 10 percent from pro forma Operating EBITDA of $353 million in the third quarter of 2017. Cost synergies and productivity, lower pension/OPEB costs and volume and price gains more than offset higher raw material and freight costs and the absence of prior year one-time gains.

Safety & Construction net sales were $4,112 million for the first nine months of 2018, up from $1,716 million in the first nine months of 2017. Net sales for the first nine months of 2018 were up 7 percent from pro forma net sales of $3,852 million in the first nine months of 2017 due to 4 percent of volume growth, a 2 percent benefit from currency and a 1 percent increase in local price.

Volume growth in the segment was driven by broad-based demand in industrial applications, with strength in NOMEX® and KEVLAR®, as well as gains in TYVEK® enterprise and water solutions. The increase in local price was due to price gains across most businesses.

Operating EBITDA was $1,084 million for the first nine months of 2018, up 19 percent from pro forma Operating EBITDA of $908 million in the first nine months of 2017, due to lower pension/OPEB costs, cost synergies, volume and price gains and favorable currency, partially offset by higher raw material and freight costs and the absence of prior year one-time gains.

### CORPORATE

Corporate includes certain enterprise and governance activities (including insurance operations, environmental operations, geographic management, etc.); business incubation platforms; non-business aligned joint ventures; gains and losses on the sales of financial assets; non-business aligned litigation expenses; discontinued or non-aligned businesses and pre-commercial activities.

*In millions*

| Corporate | Three Months Ended Sep 30, 2018 | Sep 30, 2017 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $78 | $157 | $229 | $324 |
| Pro forma net sales |  | $159 |  | $331 |
| Operating EBITDA | $(185) |  | $(536) |  |
| Pro forma Operating EBITDA |  | $(224) |  | $(627) |
| Equity earnings (losses) | $(4) | $10 | $(26) | $(8) |

Net sales for Corporate, which primarily relate to Dow's insurance operations, were $78 million in the third quarter of 2018, compared with net sales of $157 million and pro forma net sales of $159 million in the third quarter of 2017. For the first nine months of 2018, net sales were $229 million, compared with net sales of $324 million and pro forma net sales of $331 million in the same period of 2017.

Operating EBITDA was a loss of $185 million in the third quarter of 2018, compared with a pro forma Operating EBITDA loss of $224 million in the third quarter of 2017. In the first nine months of 2018, Operating EBITDA was a loss of $536 million compared with a pro forma Operating EBITDA loss of $627 million in the same period last year. Compared with pro forma Operating EBITDA in the first nine months of 2017, Operating EBITDA improved primarily due to lower pre-commercial expenses, lower discontinued business costs and cost synergies.

### SUPPLEMENTAL DIVISION INFORMATION

Discussion of segment revenue, operating EBITDA and price/volume metrics on a divisional basis for Agriculture is based on the results of the Agriculture segment; for Materials Science is based on the combined results of the Performance Materials & Coatings segment, the Industrial Intermediates & Infrastructure segment and the Packaging & Specialty Plastics segment; and for Specialty Products is based on the combined results of the Electronics & Imaging segment, the Nutrition & Biosciences segment, the Transportation & Advanced Polymers segment and the Safety & Construction segment. The Corporate segment is not included in the division metrics. The segment disclosures have been presented in this manner for informational purposes only and should not be viewed as an indication of each division’s current or future operating results on a standalone basis assuming completion of the Intended Business Separations. See the section entitled “Segment Results” for additional qualitative analysis on segment performance.

*In millions*

| Net Sales by Division | Three Months Ended Sep 30, 2018 | Sep 30, 2017 1 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 1 |
| --- | ---: | ---: | ---: | ---: |
| Agriculture | $1,946 | $1,911 | $11,484 | $11,555 |
| Performance Materials & Coatings | 2,476 | 2,227 | 7,379 | 6,558 |
| Industrial Intermediates & Infrastructure | 3,821 | 3,226 | 11,421 | 9,086 |
| Packaging & Specialty Plastics | 6,119 | 5,490 | 18,228 | 16,300 |
| Materials Science | $12,416 | $10,943 | $37,028 | $31,944 |
| Electronics & Imaging | 1,195 | 1,197 | 3,551 | 3,582 |
| Nutrition & Biosciences | 1,678 | 1,466 | 5,173 | 4,371 |
| Transportation & Advanced Polymers | 1,408 | 1,299 | 4,301 | 3,834 |
| Safety & Construction | 1,402 | 1,310 | 4,112 | 3,852 |
| Specialty Products | $5,683 | $5,272 | $17,137 | $15,639 |

| Net Sales Variance by Division 1 Local Price & Product Mix Percent change from prior year | Three Months Ended Sep 30, 2018 Currency | Volume | Portfolio / Other 2 | Total | Local Price & Product Mix | Nine Months Ended Sep 30, 2018 Currency | Volume | Portfolio / Other 2 | Total |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Agriculture | 3% | (6)% | 8% | (3)% | 2% | 3% | 1% | (4)% | (1)% | (1)% |
| Materials Science | 7% | —% | 6% | —% | 13% | 6% | 2% | 8% | —% | 16% |
| Specialty Products | 2% | —% | 3% | 3% | 8% | 2% | 2% | 3% | 3% | 10% |
| Total | 5% | (1)% | 5% | 1% | 10% | 4% | 2% | 4% | 1% | 11% |

*In millions*

| Operating EBITDA by Division | Three Months Ended Sep 30, 2018 | Sep 30, 2017 1 | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 1 |
| --- | ---: | ---: | ---: | ---: |
| Agriculture | $(104) | $(239) | $2,472 | $2,387 |
| Performance Materials & Coatings | 628 | 460 | 1,749 | 1,374 |
| Industrial Intermediates & Infrastructure | 654 | 676 | 1,990 | 1,605 |
| Packaging & Specialty Plastics | 1,191 | 1,147 | 3,822 | 3,424 |
| Materials Science | $2,473 | $2,283 | $7,561 | $6,403 |
| Electronics & Imaging | 412 | 411 | 1,217 | 1,259 |
| Nutrition & Biosciences | 414 | 312 | 1,265 | 944 |
| Transportation & Advanced Polymers | 430 | 325 | 1,313 | 954 |
| Safety & Construction | 389 | 353 | 1,084 | 908 |
| Specialty Products | $1,645 | $1,401 | $4,879 | $4,065 |

1\. Information for the three and nine months ended September 30, 2017, was prepared on a pro forma basis.

2\. Pro forma net sales for Agriculture excludes sales related to the November 30, 2017, divestiture of a portion of the DAS Divested Ag Business for the period January 1, 2017 through August 31, 2017. Sales for the month of September 2017 are included in Portfolio & Other. Pro forma net sales for Materials Science excludes sales related to the September 1, 2017, divestiture of the EAA Business for the period January 1, 2017 through August 31, 2017. Portfolio & Other includes sales for the acquisition of the H&N Business acquired on November 1, 2017, impacting Specialty Products. Portfolio & Other also reflects the following divestitures: SKC Haas Display Films group of companies (divested June 30, 2017), the authentication business (divested on January 6, 2017), and the divestiture of the global food safety diagnostic business (divested February 28, 2017), all impacting Specialty Products.

### CHANGES IN FINANCIAL CONDITION

The Company had cash and cash equivalents and marketable securities of $7,309 million at September 30, 2018 and $14,394 million at December 31, 2017, of which $5,572 million at September 30, 2018 and $12,177 million at December 31, 2017, was held by subsidiaries in foreign countries, including United States territories. For each of its foreign subsidiaries, the Company makes an assertion regarding the amount of earnings intended for permanent reinvestment, with the balance available to be repatriated to the United States.

The Company is currently evaluating the impact of The Act on its permanent reinvestment assertion. The Act requires companies to pay a one-time transition tax on earnings of foreign subsidiaries, a majority of which were previously considered permanently reinvested by the Company (see Note 7 to the Consolidated Financial Statements for further details of The Act). A tax liability was accrued for the estimated U.S. federal tax on all unrepatriated earnings at December 31, 2017, in accordance with The Act. The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries' operational activities and future foreign investments. The Company has the ability to repatriate additional funds to the U.S., which could result in an adjustment to the tax liability for foreign withholding taxes, foreign and/or U.S. state income taxes and the impact of foreign currency movements. During 2018, the Company has and expects to continue repatriating certain funds from its non-U.S. subsidiaries that are not needed to finance local operations or separation activities. During the three and nine months ended September 30, 2018, the Company recorded tax expense of $61 million associated with these repatriation activities.

The Company’s cash flows from operating, investing and financing activities, as reflected in the consolidated statements of cash flows, are summarized in the following table.

*In millions*

| Cash Flow Summary Cash provided by (used for): | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 1 |
| --- | ---: | ---: |
| Operating activities | $(370) | $(2,522) |
| Investing activities | (1,439) | 10,154 |
| Financing activities | (4,484) | (1,310) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (246) | 254 |
| Cash reclassified as held for sale | — | (37) |
| Summary |  |  |
| Increase (Decrease) in cash, cash equivalents and restricted cash | $(6,539) | $6,539 |
| Cash, cash equivalents and restricted cash at beginning of period | 14,015 | 6,624 |
| Cash, cash equivalents and restricted cash at end of period | $7,476 | $13,163 |
| Less: Restricted cash and cash equivalents, included in "Other current assets" | 537 | 15 |
| Cash and cash equivalents at end of period | $6,939 | $13,148 |

1\. Updated for ASU 2016-15 (including SEC interpretive guidance) and ASU 2016-18. See Notes 1 and 2 to the Consolidated Financial Statements for additional information.

#### Cash Flows from Operating Activities

In the first nine months of 2018, cash used for operating activities was $370 million, compared with cash used for operating activities of $2,522 million in the same period last year. In the first nine months of 2018, cash used for working capital requirements, pension contributions and integration and separation costs more than offset cash earnings. In the first nine months of 2017, cash used for working capital requirements, cash payments related to the Bayer CropScience arbitration matter and the PFOA multi-district litigation settlement and pension contributions more than offset cash earnings, a one-time cash receipt from the Nova patent infringement award and advance payments from customers for long-term ethylene supply agreements.

*In millions*

| Net Working Capital | Sep 30, 2018 | Dec 31, 2017 |
| --- | ---: | ---: |
| Current assets | $45,405 | $49,893 |
| Current liabilities | 27,680 | 26,128 |
| Net working capital | $17,725 | $23,765 |
| Current ratio | 1.64:1 | 1.91:1 |

80

#### Cash Flows from Investing Activities

In the first nine months of 2018, cash used for investing activities was $1,439 million, reflecting capital expenditures and purchases of investments, which more than offset proceeds from sales and maturities of investments and proceeds from interests in trade accounts receivable conduits. In the first nine months of 2017, cash provided by investing activities was $10,154 million, primarily due to proceeds from interests in trade accounts receivable conduits, cash acquired in the Merger and proceeds from sales and maturities of investments which more than offset capital expenditures and investments in and loans to nonconsolidated affiliates, primarily with Sadara.

Capital spending was $2,558 million in the first nine months of 2018, compared with $2,301 million in the first nine months of 2017. The Company expects full year capital spending in 2018 to be approximately $4.4 billion to $4.7 billion, inclusive of capital spending for targeted cost synergy and business separation projects.

In the first nine months of 2018, Dow entered into a shareholder loan reduction agreement with Sadara and converted $215 million of the existing loan balance into equity. Dow expects to loan between zero and $200 million to Sadara during the remainder of 2018. All or a portion of the outstanding loans to Sadara could potentially be converted into equity in future periods.

#### Cash Flows from Financing Activities

In the first nine months of 2018, cash used for financing activities was $4,484 million compared with $1,310 million in the same period last year. The increase was primarily due to purchases of treasury stock, increased payments on long-term debt, increased dividends paid to stockholders and lower proceeds from sales/issuance of common stock, which were partially offset by an increase in notes payable and proceeds from issuance of long-term debt.

#### Reclassification of Prior Period Amounts Related to Accounts Receivable Securitization

In connection with the review and implementation of ASU 2016-15, including additional interpretive guidance from the SEC related to the required method for calculating the cash received from beneficial interests in trade accounts receivable conduits, Dow changed the prior period presentation and amount of proceeds from interests in trade accounts receivable conduits. In the first nine months of 2017, changes related to the calculation and presentation of proceeds from interests in trade accounts receivable conduits resulted in a reclassification of $6,989 million from cash used for operating activities to cash provided by investing activities. In the fourth quarter of 2017, Dow suspended further sales of trade accounts receivable through these facilities and began reducing outstanding balances through collections of trade accounts receivable previously sold to such conduits. In September and October 2018, the North American and European facilities, respectively, were amended and the terms of the agreements changed from off-balance sheet arrangements to secured borrowing arrangements.

The following table reconciles cash flows from operating activities to a non-GAAP measure regarding cash flows from operating activities excluding the impact of ASU 2016-15 and related interpretive guidance for the nine months ended September 30, 2018 and 2017. Management believes this non-GAAP financial measure is relevant and meaningful as it presents cash flows from operating activities inclusive of all trade accounts receivable collection activity, which the Company utilizes in support of its operating activities.

*In millions*

| Cash Flows from Operating Activities Excluding the Impact of ASU 2016-15 and Additional Interpretive Guidance (non-GAAP) Sep 30, 2018 | Nine Months Ended Sep 30, 2017 |  |
| --- | ---: | ---: |
| Cash flows from operating activities - Updated for impact of ASU 2016-15 and additional interpretive guidance (GAAP) | $(370) | $(2,522) |
| Less: Impact of ASU 2016-15 and additional interpretive guidance | (657) | (6,989) |
| Cash flows from operating activities - Excluding impact of ASU 2016-15 and additional interpretive guidance (non-GAAP) | $287 | $4,467 |

### Free Cash Flow

The Company defines free cash flow as cash from operating activities less capital expenditures. Under this definition, free cash flow represents the cash that remains available to the Company, after investing in its asset base, to fund obligations using the Company's primary source of incremental liquidity - cash flows from operating activities. Free cash flow is an integral financial measure used in the Company's financial planning process. This financial measure is not recognized in accordance with U.S. GAAP and should not be viewed as an alternative to U.S. GAAP financial measures of performance. All companies do not calculate non-GAAP financial measures in the same manner and, accordingly, the Company's free cash flow definition may not be consistent with the methodologies used by other companies.

For additional information relating to the change in cash used for operating activities, see the discussion in the previous section entitled "Cash Flows from Operating Activities."

*In millions*

| Reconciliation of "Cash From Operating Activities" to Free Cash Flow (non-GAAP) | Nine Months Ended Sep 30, 2018 | Sep 30, 2017 1 |
| --- | ---: | ---: |
| Cash from operating activities (GAAP) | $(370) | $(2,522) |
| Less: Capital expenditures | 2,558 | 2,301 |
| Free cash flow (non-GAAP) | $(2,928) | $(4,823) |

1\. "Cash from operating activities" was updated for ASU 2016-15 (including SEC interpretive guidance) and ASU 2016-18. See Notes 1 and 2 to the Consolidated Financial Statements for additional information.

### Liquidity & Financial Flexibility

The Company’s primary source of incremental liquidity is cash flows from operating activities. Management expects the generation of cash from operations and the ability to access the debt capital markets and other sources of liquidity will continue to provide sufficient liquidity and financial flexibility to meet the Company’s and its subsidiaries obligations as they come due.

### Dow's Liquidity Sources

#### Credit Ratings

At October 31, 2018, Dow's credit ratings were as follows:

|  |  |  |  |
| --- | --- | --- | --- |
| **Credit Ratings** | Long-Term Rating | Short-Term Rating | Outlook |
| Standard & Poor’s | BBB | A-2 | Stable |
| Moody’s Investors Service | Baa2 | P-2 | Stable |
| Fitch Ratings | BBB | F2 | Rating Watch Positive |

Downgrades in Dow's credit ratings would increase borrowing costs on certain indentures and could impact its ability to access credit markets.

#### Commercial Paper - Dow

Dow issues promissory notes under U.S. and Euromarket commercial paper programs. At September 30, 2018, Dow had $594 million of commercial paper outstanding ($231 million at December 31, 2017). Dow maintains access to the commercial paper market at competitive rates. Amounts outstanding under Dow's commercial paper programs during the period may be greater, or less, than the amount reported at the end of the period.

#### Committed Credit Facilities - Dow

In the event the Company has short-term liquidity needs, it can access liquidity through Dow's committed and available credit facilities. On May 27, 2018, Dow renewed a $200 million Bilateral Revolving Credit Facility agreement, which has a maturity date in May 2020 and provides for interest at floating rates, as defined in the agreement. On July 20, 2018, Dow renewed a $200 million Bilateral Revolving Credit Facility agreement, which has a maturity date in July 2020 and provides for interest at floating rates, as defined in the agreement. On August 4, 2018, Dow renewed a $100 million Bilateral Revolving Credit Facility agreement, which has a maturity date in August 2020 and provides for interest at floating rates, as defined in the agreement.

On October 30, 2018, Dow terminated and replaced its $5.0 billion Five Year Competitive Advance and Revolving Credit Facility Agreement under substantially similar terms and conditions, which has a maturity date in October 2023. In addition, Dow amended a $100 million Bilateral Revolving Credit Facility agreement, which has a maturity date in October 2019 and provides for interest at floating rates, as defined in the agreement.

In connection with the Dow Silicones ownership restructure, on May 31, 2016, Dow Silicones incurred $4.5 billion of indebtedness under a certain third party credit agreement ("Dow Term Loan Facility"). Dow subsequently guaranteed the obligations of Dow Silicones under the Dow Term Loan Facility and, as a result, the covenants and events of default applicable to the Dow Term Loan Facility are substantially similar to the covenants and events of default set forth in Dow's Five Year Competitive Advance and Revolving Credit Facility. In the second quarter of 2018, Dow Silicones exercised a 19-month extension option making amounts borrowed under the Dow Term Loan Facility repayable on December 30, 2019, and amended the Dow Term Loan Facility to include an additional 2-year extension option, at Dow Silicones' election, upon satisfaction of certain customary conditions precedent.

In September 2018, Dow renewed its North American accounts receivable securitization facility for a one year term and amended the terms of the agreement from an off-balance sheet arrangement to a secured borrowing arrangement, with a borrowing capacity up to $800 million. Under the structure of the amended agreement, Dow will use select trade accounts receivable to collateralize the credit facility with certain lenders. At September 30, 2018, the facility had not been drawn upon.

At September 30, 2018, Dow had total committed credit facilities of $11.7 billion with remaining available credit facilities of $7.2 billion.

In October 2018, Dow renewed its European accounts receivable securitization facility for a two year term and amended the terms of the agreement from an off-balance sheet arrangement to a secured borrowing arrangement, with a borrowing capacity up to Euro 400 million. Under the structure of the amended agreement, Dow will use select trade accounts receivable to collateralize the credit facility with certain lenders. See Note 15 to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, for additional information on committed and available credit facilities.

### DuPont's Liquidity Sources

#### Credit Ratings

At October 31, 2018, DuPont's credit ratings were as follows:

|  |  |  |  |
| --- | --- | --- | --- |
| **Credit Ratings** | Long-Term Rating | Short-Term Rating | Outlook |
| Standard & Poor’s | A- | A-2 | Stable |
| Moody’s Investors Service | A3 | P-2 | Negative |
| Fitch Ratings | A | F1 | Rating Watch Negative |

Downgrades in DuPont's credit ratings would increase borrowing costs on certain indentures and could impact its ability to access debt capital markets.

#### Commercial Paper - DuPont

DuPont issues promissory notes under U.S. commercial paper programs. At September 30, 2018, DuPont had $2,518 million of commercial paper outstanding ($1,436 million at December 31, 2017). DuPont maintains access to the commercial paper market at competitive rates. Amounts outstanding under DuPont's commercial paper programs during the period may be greater, or less, than the amount reported at the end of the period.

#### Committed Credit Facilities - DuPont

In the event the Company has short-term liquidity needs, it can access liquidity through DuPont's committed and available credit facilities. At September 30, 2018, DuPont had total committed credit facilities of $8.8 billion with remaining available credit facilities of $5.5 billion. See Note 15 to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, for additional information on committed and available credit facilities.

#### Term Loan and Revolving Credit Facilities - DuPont

In March 2016, DuPont entered into a credit agreement that provides for a three-year, senior unsecured term loan facility in the aggregate principal amount of $4.5 billion (as may be amended, from time to time, the "Term Loan Facility") under which DuPont may make up to seven term loan borrowings and amounts repaid or prepaid are not available for subsequent borrowings. The proceeds from the borrowings under the Term Loan Facility will be used for DuPont's general corporate purposes including debt repayment, working capital and funding a portion of the Company's costs and expenses. The Term Loan Facility was amended in 2018 to extend the maturity date to June 2020, at which time all outstanding borrowings, including accrued but unpaid interest, become immediately due and payable, and to extend the date on which the commitment to lend terminates to June 2019. At September 30, 2018, DuPont had made four term loan borrowings in an aggregate principal amount of $2.0 billion and had unused commitments of $2.5 billion under the Term Loan Facility. In addition, in 2018, DuPont amended its $3.0 billion revolving credit facility to extend the maturity date to June 2020.

#### Committed Receivable Repurchase Facility - DuPont

In February 2018, in line with seasonal agricultural working capital requirements, DuPont entered into a committed receivable repurchase agreement of up to $1.3 billion (the "2018 Repurchase Facility") which expires in December 2018. From time to time, DuPont and the banks modify the monthly commitment amounts to better align with working capital requirements. Under the 2018 Repurchase Facility, DuPont may sell a portfolio of available and eligible outstanding customer notes receivables within the Agriculture segment to participating institutions and simultaneously agree to repurchase at a future date. See Note 12 to the Consolidated Financial Statements for additional information.

### Debt

The Company’s public debt instruments and primary, private credit agreements (collectively "Debt Instruments") reside with Dow and DuPont (the "Subsidiaries"). See Note 12 to the Consolidated Financial Statements for information related to the Subsidiaries' notes payable and long-term debt activity since December 31, 2017, including debt retired and issued. The following table reflects the debt of the Subsidiaries:

*In millions*

| Total Debt | Sep 30, 2018 Dow | DuPont | Total | Dec 31, 2017 Dow | DuPont | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Notes payable | $910 | $3,847 | $4,757 | $484 | $1,464 | $1,948 |
| Long-term debt due within one year | 2,605 | 513 | 3,118 | 752 | 1,315 | 2,067 |
| Long-term debt | 17,085 | 10,208 | 27,293 | 19,765 | 10,291 | 30,056 |
| Total debt | $20,600 | $14,568 | $35,168 | $21,001 | $13,070 | $34,071 |

The Debt Instruments of the Subsidiaries contain, among other provisions, certain customary restrictive covenant and default provisions. Dow’s Five Year Competitive Advance and Revolving Credit Facility contains a financial covenant that Dow must maintain its ratio of consolidated indebtedness to its consolidated capitalization at no greater than 0.65 to 1.00 at any time the aggregate outstanding amount of loans under the Five Year Competitive Advance and Revolving Credit Facility equals or exceeds $500 million. The ratio of Dow’s consolidated indebtedness to its consolidated capitalization was 0.41 to 1.00 at September 30, 2018. DuPont’s Term Loan Facility and revolving credit facility contain a financial covenant requiring that the ratio of total indebtedness to total capitalization for DuPont and its consolidated subsidiaries not exceed 0.6667 to 1.00. At September 30, 2018, management believes each of the Subsidiaries were in compliance with all of their respective covenants and default provisions. For additional information on the Subsidiaries' debt covenants and default provisions, see Note 15 to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.

### Dividends

On June 25, 2018, the Company announced that its Board declared a dividend of $0.38 per share, paid on September 14, 2018, to shareholders of record on August 31, 2018.

On October 11, 2018, the Company announced that its Board declared a dividend of $0.38 per share, payable on December 14, 2018, to shareholders of record on November 30, 2018.

### Share Repurchase Programs

On November 2, 2017, the Company announced the Board authorized an initial $4 billion share repurchase program, which had no expiration date. The Company spent $1 billion on repurchases of DowDuPont common stock under the program in the fourth quarter of 2017. In the first nine months of 2018, the Company spent $3 billion on repurchases of DowDuPont common stock under the program, thereby completing this share repurchase program.

On November 1, 2018, the Company announced a new $3 billion share buyback program, which expires on March 31, 2019 - commensurate with the expected timing of the materials science spin-off.

See Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds, for additional information.

### Pension Plans

Dow and DuPont have defined benefit pension plans in the U.S. and a number of other countries. Dow and DuPont did not merge their pension plans and other postretirement benefit plans as a result of the Merger. Dow and DuPont's funding policies are to contribute to defined benefit pension plans in the U.S. and a number of other countries based on pension funding laws and local country requirements. Contributions exceeding funding requirements may be and have been made at Dow and DuPont's discretion.

In the third quarter of 2018, Dow made a $1,100 million discretionary contribution to its principal U.S. pension plan and increased its total 2018 estimated pension contributions to approximately $1,600 million, of which $1,538 million had been contributed through September 30, 2018.

In the third quarter of 2018, DuPont made a $1,100 million discretionary contribution to its principal U.S. pension plan and increased its total 2018 estimated pension contributions to approximately $1,300 million, of which $1,266 million had been contributed through September 30, 2018.

The discretionary contributions made in the third quarter of 2018 were aligned with each of Dow and DuPont’s funding policies, which may permit discretionary contributions to defined benefit pension plans when economics encourage funding, and reflected considerations relating to tax deductibility and capital structure.

For additional information regarding Dow and DuPont's pension plans, see Note 16 to the Consolidated Financial Statements and Note 19 to the Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.

### Restructuring

#### DowDuPont Cost Synergy Program

The activities related to the DowDuPont Cost Synergy Program ("Synergy Program") are expected to result in additional cash expenditures of approximately $840 million to $990 million, primarily by the end of 2019, consisting of severance and related benefit costs and costs associated with exit and disposal activities, including environmental remediation (see Note 5 to the Consolidated Financial Statements). The Company expects to incur additional costs in the future related to its restructuring activities. Future costs are expected to include demolition costs related to closed facilities and restructuring plan implementation costs; these costs will be recognized as incurred. The Company also expects to incur additional employee-related costs, including involuntary termination benefits, related to its other optimization activities. These costs cannot be reasonably estimated at this time.

### Contractual Obligations

Information related to the Company’s contractual obligations, commercial commitments and expected cash requirements for interest can be found in the Company's 2017 Annual Report on Form 10-K, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Liquidity and Capital Resources. Additional information related to these obligations can be found in Notes 15, 16 and 19 to the Consolidated Financial Statements in the Company’s 2017 Annual Report on Form 10-K. With the exception of the items noted below, there have been no material changes in the Company’s contractual obligations since December 31, 2017.

*In millions*

| Contractual Obligations | Payments Due In 2018 | 2019-2020 | 2021-2022 | 2023 and beyond | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Purchase obligations 1 | $4,060 | $5,956 | $4,701 | $7,562 | $22,279 |
| Pension and other postretirement benefits | $224 | $1,521 | $1,668 | $12,524 | $15,937 |

1\. Includes take-or-pay and throughput obligations and outstanding purchase orders and other commitments greater than $1 million, obtained through a survey conducted by the Subsidiaries.

### Off-balance Sheet Arrangements

Off-balance sheet arrangements are obligations the Company has with nonconsolidated entities related to transactions, agreements or other contractual arrangements. The Company holds variable interests in joint ventures accounted for under the equity method of accounting. The Company is not the primary beneficiary of these joint ventures and therefore is not required to consolidate the entities (see Note 20 to the Consolidated Financial Statements). In addition, see Note 11 to the Consolidated Financial Statements for information regarding transfers of financial assets.

Guarantees arise in the ordinary course of business from relationships with customers and nonconsolidated affiliates when the Subsidiaries undertake an obligation to guarantee the performance of others if specific triggering events occur. The Subsidiaries had combined outstanding guarantees at September 30, 2018, of $5,771 million, compared with $5,960 million at December 31, 2017. Additional information related to the guarantees of the Subsidiaries can be found in the “Guarantees” section of Note 13 to the Consolidated Financial Statements.

### Fair Value Measurements

See Note 19 to the Consolidated Financial Statements for additional information concerning fair value measurements.

### OTHER MATTERS

### Recent Accounting Guidance

See Note 2 to the Consolidated Financial Statements for a summary of recent accounting guidance.

### Critical Accounting Estimates

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make judgments, assumptions and estimates that affect the amounts reported in the consolidated financial statements and accompanying notes. Note 1 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 10-K”) describes the significant accounting policies and methods used in the preparation of the consolidated financial statements. DowDuPont’s accounting policies that are impacted by judgments, assumptions and estimates are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s 2017 10-K. Since December 31, 2017, there have been no material changes in the Company’s accounting policies that are impacted by judgments, assumptions and estimates. See the discussion in this section for information regarding the Company's interim goodwill impairment testing.

### Asbestos-Related Matters of Union Carbide Corporation

Union Carbide is and has been involved in a large number of asbestos-related suits filed primarily in state courts during the past four decades. These suits principally allege personal injury resulting from exposure to asbestos-containing products and frequently seek both actual and punitive damages. The alleged claims primarily relate to products that Union Carbide sold in the past, alleged exposure to asbestos-containing products located on Union Carbide’s premises, and Union Carbide’s responsibility for asbestos suits filed against a former Union Carbide subsidiary, Amchem Products, Inc. ("Amchem"). In many cases, plaintiffs are unable to demonstrate that they have suffered any compensable loss as a result of such exposure, or that injuries incurred in fact resulted from exposure to Union Carbide’s products.

The table below provides information regarding asbestos-related claims pending against Union Carbide and Amchem based on criteria developed by Union Carbide and its external consultants.

| Asbestos-Related Claim Activity | 2018 | 2017 |
| --- | ---: | ---: |
| Claims unresolved at Jan 1 | 15,427 | 16,141 |
| Claims filed | 5,279 | 5,598 |
| Claims settled, dismissed or otherwise resolved | (7,861) | (6,560) |
| Claims unresolved at Sep 30 | 12,845 | 15,179 |
| Claimants with claims against both Union Carbide and Amchem | (4,778) | (5,544) |
| Individual claimants at Sep 30 | 8,067 | 9,635 |

Plaintiffs’ lawyers often sue numerous defendants in individual lawsuits or on behalf of numerous claimants. As a result, the damages alleged are not expressly identified as to Union Carbide, Amchem or any other particular defendant, even when specific damages are alleged with respect to a specific disease or injury. In fact, there are no personal injury cases in which only Union Carbide and/or Amchem are the sole named defendants. For these reasons and based upon Union Carbide’s litigation and settlement experience, Union Carbide does not consider the damages alleged against Union Carbide and Amchem to be a meaningful factor in its determination of any potential asbestos-related liability.

For additional information, see Asbestos-Related Matters of Union Carbide Corporation in Note 13 to the Consolidated Financial Statements and Part II, Item 1. Legal Proceedings.

### Valuation of Assets and Impairment Considerations

As a result of the Merger and the related acquisition method of accounting, DuPont’s assets and liabilities were measured at fair value, and any declines in the projected cash flows could have a material, negative impact on the fair value of the Company’s reporting units and assets, particularly within the Agriculture and Specialty Products divisions, and therefore could result in an impairment.

As previously disclosed in the Form 10-Q for the quarter ended June 30, 2018, the Company commenced strategic business reviews during the third quarter of 2018 inclusive of assembling updated financial projections. During the three months ended September 30, 2018, and in connection with these strategic business reviews and the update to financial projections, DowDuPont’s subsidiary, DuPont, a separate SEC registrant, was required to perform an interim test of goodwill for its agriculture reporting unit. As a result of the analysis performed, DuPont recorded a pretax, noncash goodwill impairment charge of $4.5 billion in its stand-alone quarterly report on Form 10-Q for the quarter ended September 30, 2018. However, the impairment charge did not survive at the DowDuPont level. The impairment test performed for DowDuPont’s Agriculture reporting unit is based on a combination of DuPont’s agriculture reporting unit and Dow’s agriculture reporting unit. Based on the analysis performed at the DowDuPont level, the fair value of the combined Agriculture reporting unit exceeded its carrying value by more than 10 percent, and therefore no goodwill impairment existed for DowDuPont.

The Company also performed an impairment test on indefinite-lived intangibles and determined that the fair value of certain IPR&D assets had declined as a result of delays in timing of commercialization and increases to expected R&D costs. This resulted in a pretax impairment charge of $85 million. The assumptions and estimates used in determining the fair values of this reporting unit and its indefinite-lived intangibles contain uncertainties, and any changes to these assumptions and estimates could have a negative impact and result in a future impairment. See Note 10 to the Consolidated Financial Statements for additional information on the impairment test performed.

There were no other indicators for the Company’s other reporting units that would suggest that it is more likely than not that the fair value is less than its carrying value at September 30, 2018; however, there can be no assurances that goodwill will not be impaired in future periods. The Company will perform its annual goodwill and intangible asset impairment test in the fourth quarter, which may result in additional impairments. For additional information see Note 10 to the Consolidated Financial Statements.

## Market risk

As filed, 316 characters.

See Note 18 to the Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the Company's 2017 Annual Report on Form 10-K for information on the Company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

## Controls and procedures

As filed, 1,169 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out an evaluation, under the supervision and with the participation of the Company’s Disclosure Committee and the Company’s management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to paragraph (b) of Exchange Act Rules 13a-15 and 15d-15. Based upon that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective.

### Changes in Internal Control Over Financial Reporting

There were no changes in the Company's internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that was conducted during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

### DowDuPont Inc. PART II - OTHER INFORMATION

## Risk factors

As filed, 191 characters.

There have been no material changes in the Company's risk factors discussed in Part I, Item 1A, Risk Factors, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

Filed Nov 2, 2018.
Source: SEC EDGAR, the filing index for accession 0001666700-18-000060. Last ingested by Listed: Nov 10, 2026, 16:51 ET. No prices; not investment advice.
